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Intraductal papillary mucinous neoplasms (IPMNs) are precancerous lesions that 
can progress to invasive pancreatic cancer and a key system in which to study early 
pancreatic tumorigenesis. We used a combination of multi-region and single-cell 
targeted next generation sequencing to assess the diversity of somatic driver gene 
mutations in IPMNs. The resulting data, combined with evolutionary modeling, whole 
exome sequencing, and in situ mutation detection, show that the earliest stages of 
pancreatic tumorigenesis are characterized by independent clones with distinct early 
driver gene mutations, thus revealing the polyclonal origin of precancerous pancreatic 
neoplasms. In addition, multiple mutations in later-occurring driver genes were also 
common and were frequently localized to unique tumor clones, raising the possibility of 
convergent evolution of these genetic events in pancreatic tumorigenesis. Collectively, 
our data demonstrate substantial genetic heterogeneity within IPMN, predominately in 
IPMNs with low-grade dysplasia. These data also challenge traditional monoclonal 
tumor origin models and transform our understanding of the evolutionary history of 
pancreatic neoplasia. Understanding the mechanism underlying polyclonal precancers 
may reveal new strategies to identify patients at increased risk of developing invasive 
pancreatic cancer. 
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Pancreatic cancer is expected to be the second leading cause of cancer-related 
deaths in the U.S. by 2030, with a current 5-year survival rate of only 8%[1,2]. This 
dismal prognosis is largely due to a lack of early clinical symptoms, with many patients 
already presenting with advanced disease at initial diagnosis. Therefore, early detection 
approaches will be critical to improve outcomes in this disease. A great opportunity for 
early detection is the treatment of premalignant pancreatic lesions, including pancreatic 
intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). 
However, prevention of pancreatic cancer must be balanced with potential 
overtreatment of low-risk lesions. Recent advances in sequencing technologies have 
deepened our understanding of the genetic changes that characterize these lesions, 
which offer new opportunities for screening and early detection. While the majority of 
PDACs likely arise through PanINs, IPMNs present unique clinical challenges as they 
are common in the population and are often incidentally identified on routine abdominal 
imaging[3]. Moreover, their size and resultant early clinical intervention provide critical 
human tissue samples, which can be used to interrogate early pancreatic neoplasia. 
Intraductal Papillary Mucinous Neoplasm (IPMN) 
IPMN is a common precursor to pancreatic cancer and the most common cyst of 
the pancreas. Originally thought to be uncommon, improvements and expanded use of 
imaging modalities have revealed that nearly 14% of the U.S. adult population harbors a 
pancreatic cyst[3,4]. IPMNs are grossly visible (>1cm in diameter), mucin-producing 
neoplastic cysts that arise within the main pancreatic duct or branch ducts[5]. IPMNs 




intermediate, or high-grade. This classification was revised to a two-tier system where 
the former intermediate-grade category is now considered low-grade[6]. IPMNs are also 
categorized by histologic subtype based on the direction of differentiation of the lining 
epithelium: gastric, intestinal, pancreatobiliary, and oncocytic. Recently, oncocytic-type 
IPMNs, often referred to as intraductal oncocytic papillary neoplasms (IOPNs), were 
shown to be unique neoplasms from IPMNs and genetically distinct from the other 
histologic subtypes[7,8]. Gastric, intestinal and pancreatobiliary-type IPMNs can 
progress to conventional ductal/tubular carcinomas, while intestinal-type IPMNs can 
also give rise to colloid carcinomas characterized by extensive stromal mucin 
accumulation[9,10]. The risk of malignancy associated with an IPMN varies depending 
on numerous factors (i.e. size, location, grade of dysplasia), with 30-50% of surgically 
resected IPMNs harboring invasive carcinoma[11–13]. Molecular studies of IPMN have 
demonstrated that the progression from low-grade IPMN to high-grade IPMN is 
associated with an accumulation of genetic changes that eventually give rise invasive 
carcinoma[14]. Therefore, an understanding of the molecular drivers that characterize 
IPMNs is critical for developing effective early detection strategies for pancreatic cancer. 
Molecular Features of IPMN 
Numerous studies have identified genetic alterations that play a key role in IPMN 
tumorigenesis. The most common alterations in IPMN are somatic mutations in the 
oncogenes KRAS and GNAS. Mutations in KRAS occur in 50-80% of all IPMNs and are 
thought to be an early event of IPMN development[15–18]. The identification of GNAS 
mutations in IPMN was pioneered by Wu et al, which defined a new pathway for 




all IPMNs and remarkably, are not typically found in other pancreatic precursors or in 
invasive PDAC not associated with an IPMN[18–21]. In association with IPMN, GNAS 
mutations are found in 23-37% of invasive carcinomas[18,21,22]. GNAS encodes the 
alpha-subunit of a stimulatory guanine nucleotide-binding protein, which activates the 
cyclic-AMP cascade, leading to cell growth and proliferation[23]. GNAS mutations are 
most prevalent in intestinal-type IPMNs, found in 70-100% of these 
neoplasms[18,19,24,25]. Overall, more than 90% of all IPMNs harbor a KRAS and/or 
GNAS mutation, making them important drivers of IPMN development. Moreover, their 
prevalence in low-grade IPMNs suggests that alterations in these oncogenes may be 
initiating events in IPMN formation. 
 Another commonly mutated gene in IPMN is RNF43, found in 10-75% of 
IPMNs[15,22,24]. Alterations in RNF43 are typically inactivating (i.e. nonsense, 
frameshift) and accompanied by loss of heterozygosity, implicating RNF43 as a tumor 
suppressor gene in IPMN tumorigenesis. The RNF43 protein is a transmembrane E3 
ubiquitin ligase that serves as a negative regulator of Wnt signaling, thereby inhibiting 
cell proliferation[26]. Whole-exome and targeted sequencing studies have identified 
mutations in RNF43 in 6-11% of all invasive PDACs, not just those associated with an 
IPMN[20,27,28]. 
Inactivation of CDKN2A/p16 has been shown to play a role in IPMN progression, 
particularly during late-stage development. Many studies performing IHC have found 
p16 loss in IPMNs with high-grade dysplasia (50-100%), and less frequently in low-
grade IPMNs (10-51%)[29,30]. However, several next-generation sequencing (NGS) 




grade IPMNs and 0-15% of high-grade IPMNs[15,17,24]. This discrepancy may be 
explained by alternative mechanisms of CDKN2A gene silencing. For example, 
epigenetic silencing by promoter hypermethlyation has been described in 21% of high-
grade IPMNs[31]. Additionally, allelic loss of chromosome 9p was found in 18-62% of 
IPMNs[32,33]. Altogether, these studies indicate that loss of CDKN2A/p16 is mediated 
by the same three mechanisms described in PanIN and is a later event in IPMN 
tumorigenesis. 
 Mutations in TP53 are extremely rare in low-grade IPMNs but appear much more 
frequently in high-grade IPMNs. Prior to the widespread use of NGS technologies, the 
literature described variable p53 expression in IPMNs[34]. Studies have found diffuse 
nuclear p53 labeling in invasive carcinomas but were unable to detect p53 expression in 
IPMN[35]. Others showed variable p53 staining in 40-50% of high-grade IPMNs[36]. 
Targeted, massively-parallel sequencing studies have identified TP53 mutations in 15-
20% of high-grade IPMNs and 0-5% of low-grade IPMNs[17,24]. These data suggest 
that TP53 mutations are late-occurring alterations and may play a role in the malignant 
progression of IPMN. 
 Unlike the previously mentioned tumor suppressor genes, loss of SMAD4 is 
mainly confined to invasive carcinomas. Several studies have analyzed the 
immunohistochemical expression of SMAD4 in IPMNs and invasive cancers[29,37,38]. 
They all found retained expression of SMAD4 in the vast majority of IPMNs, while 
typically half of invasive carcinomas show loss of SMAD4. In concordance with the IHC 
findings, targeted and whole exome sequencing studies also found SMAD4 mutations to 




polymerase-chain reaction (PCR)-based microsatellite analysis found allelic loss of 18q 
in 22-38% of IPMNs[32,33]. Overall, it seems SMAD4 inactivation is not involved in 
early-stages of IPMN development, but important for its transition to invasive carcinoma. 
 Mutations in several other cancer-related genes have been reported in IPMNs at 
low prevalence, such as PIK3CA, BRAF, PTEN, and STK11[39–43]. Mutations in the 
oncogenes PIK3CA and BRAF have also been reported to be drivers in invasive PDAC 
and many other cancer types[20]. Early studies have reported loss-of-function mutations 
in PTEN at relatively low frequencies in invasive PDAC; however, more recent studies 
have found loss of at least one copy of the PTEN gene can help drive malignant 
progression of both human and mouse PDACs[44,45]. Peutz-Jeghers syndrome 
patients have an elevated risk of pancreatic malignancy, and commonly harbor germline 
mutations in the tumor suppressor gene STK11[46,47]. Several studies have 
demonstrated LOH at the STK11 locus in sporadic PDACs and other cancers of the 
gastrointestinal tract, breast, and ovaries[48–51]. 
Early detection of IPMN 
 As mentioned previously, IPMN is a common precursor of PDAC and therefore 
represents a key target for early detection approaches. Imaging modalities, such as 
computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic 
ultrasound (EUS) are commonly used to detect lesions in the pancreas. In a multi-
institution study conducted by Canto et al, these imaging methods were used to screen 
225 asymptomatic, high-risk individuals (HRI)[52]. They found that 42% of HRIs had at 
least one pancreatic mass or a dilated pancreatic duct. Among these, proven or 




also be augmented to target specific structures and molecules. For example, Neesse et 
al designed a fluorochrome that specifically targets claudin-4[53], a protein known to be 
upregulated in pancreatic neoplasia[54,55]. 
 While these imaging-based approaches are useful to detect pancreatic cysts, 
they may not reliably differentiate cyst type or important histological features (i.e. grade 
of dysplasia), which can better predict likelihood of progression. This distinction is 
clinically important because pancreatic cysts represent a diverse group of lesions, some 
of which are low-risk while others progress to invasive carcinoma. As a result, a more 
reliable determination of precursors with a higher malignant potential will be critical. 
Many studies have demonstrated the value of collecting cyst fluid by EUS-fine needle 
aspiration from patients diagnosed with pancreatic cysts. Several reports highlight the 
importance of cytological evaluation of cyst fluid for atypical epithelial cells, which can 
serve as a predictor of malignancy[56–58]. Others have reported on the diagnostic 
value of biochemical markers in cyst-fluid for differentiating likely benign, serous cysts 
from mucinous cysts which have greater risk of malignancy[59–61]. Furthermore, two 
independent studies used targeted NGS to analyze cyst-fluid[62,63]. The investigators 
used a combination of molecular markers to categorize a cyst as IPMN with 76-100% 
sensitivity and 84-96% specificity. This approach identified IPMNs with high-grade 
dysplasia or invasive carcinoma with 88% sensitivity and 69-97% specificity. These 
results highlight the ability of cyst fluid sequencing to preoperatively determine cyst type 
as well as predict grade of dysplasia in premalignant cysts. Another marker that could 
be used to differentiate grade of dysplasia in IPMN is telomere fusion, which frequently 




method to detect telomere fusion in cyst-fluid[64]. They detected telomere fusions in 
27% of high-grade IPMNs, but not in low-grade IPMNs. Additionally, several studies 
have used cyst fluid to identify other molecular changes such as telomerase activity and 
microRNA levels[65,66]. As a result from these findings and others, several institutions 
are implementing NGS-based molecular tests using cyst fluid to aid in the clinical 
evaluation and diagnosis of pancreatic cysts. 
 While these studies provide important data for the early detection of IPMN, they 
are limited by sampling only cyst-fluid. Felsenstein et al found that a substantial portion 
of PDACs with co-occurring IPMNs are unrelated[22]; therefore, analysis of cyst fluid 
may not detect the true precursor of the cancer. A promising approach is genetic 
analysis of secretin-stimulated pancreatic juice collected from the duodenum. Yu et al 
developed a digital NGS approach to detect low-abundance mutations in pancreatic 
juice samples[67]. In two cases of high-risk individuals, digital NGS was able to detect 
SMAD4 or TP53 mutations more than one year before their pancreatic cancer 
diagnosis. Finally, Suenaga et al performed digital NGS using a targeted 12-gene panel 
to evaluate mutation concentrations in pancreatic juice samples[68]. Mutation 
concentrations in genes other than KRAS/GNAS were higher in patients with PDAC or 
high-grade precursors relative to all other subjects. Consistent with previous studies and 
the molecular progression of IPMN, this pancreatic juice analysis found several 
predictors of pancreatic cancer or a high-grade precursor: presence of SMAD4 
mutations, high SMAD4/TP53 mutation concentrations, and high overall mutation 
concentrations. While the lack of these mutations does not guarantee absence of 




test for patients undergoing pancreatic evaluation. Finally, analysis of molecules and 
cells in the blood also does not require sampling of a specific lesion in the pancreas and 
thus is an alternative approach to early detection. For example, some groups have 
reported analysis of circulating epithelial cells (CECs) in the bloodstream in patients with 
pancreatic cancer as well as IPMN[69,70]. This method has been used to detect CECs 
in patients with cystic lesions prior to the clinical diagnosis of invasive PDAC. Numerous 
serum markers have also been suggested as potential biomarkers for early detection of 
pancreatic neoplasia, but these remain to be systematically evaluated[71]. 
Genetic Heterogeneity in IPMN 
 Genetic heterogeneity of driver gene alterations in IPMN have recently been 
described due to increased sensitivity of NGS approaches. Wu et al used targeted 
sequencing to analyze cyst fluid from 19 patients[19]. They found 11% of IPMNs 
contained two different KRAS mutations, 2% contained three different KRAS mutations, 
and 4% contained two different GNAS mutations. Additionally, Felsenstein et al 
microdissected epithelium from two distinct regions of IPMN, and subsequently 
performed deep targeted sequencing of pancreatic driver genes[22]. These studies 
reported that 23% of IPMNs had multiple KRAS and/or GNAS mutations, and 
remarkably one of these IPMNs contained four unique KRAS mutations.  
In the future, more comprehensive analyses of the genetic heterogeneity in 
pancreatic cancer precursor lesions can further elucidate their clonal evolution and 
neoplastic progression. Additionally, the identification and validation of molecular 
markers that can reliably distinguish low-risk lesions from lesions with a high risk of 




These promising approaches require a deep understanding of the molecular alterations 
that occur during pancreatic tumorigenesis. 
My thesis work focused on characterizing genetic heterogeneity within IPMNs 
and exploring the evolutionary history of early pancreatic tumorigenesis. This work can 
be divided into two sections. Chapter 2 focuses on a comprehensive multi-region 
targeted sequencing study, which analyzed 227 neoplastic samples from 20 cases of 
surgically resected IPMN. This targeted sequencing data was further supported by 
evolutionary modeling, whole exome sequencing, and in-situ mutation detection. 
Chapter 3 supplements the previously mentioned work by using the novel approach of 
single-cell sequencing of IPMNs. Altogether, this thesis work utilized multiple 
sequencing-based approaches to reveal extensive driver gene heterogeneity and 
polyclonal origin of IPMN. These findings provide novel insights into the initiation and 
progression of pancreatic precancers, and advance our understanding of the origins of 
invasive pancreatic cancer.   
The following represent unanswered questions that require further investigation: 
 Why do these early pancreatic precancers contain multiple, independent 
clones? 
 What mechanisms support the growth of polyclonal pancreatic 
precancers? 
































While the majority of PDACs likely arise through PanINs, IPMNs present unique 
clinical challenges as they are common in the population and are often incidentally 
identified on routine abdominal imaging[3]. Moreover, their size and resultant early 
clinical intervention provide critical human tissue samples, which can be used to 
interrogate early pancreatic neoplasia. Molecular studies of IPMN suggest that the 
progression from low-grade to high-grade dysplasia is associated with an accumulation 
of genetic alterations in oncogenes and tumor suppressor genes, eventually leading to 
the development of invasive PDAC. Previous studies have characterized several key 
driver gene alterations in IPMNs: mutations in the oncogenes KRAS and GNAS are 
thought to be the earliest driver gene alterations, while mutations in tumor suppressor 
genes such as RNF43, CDKN2A, and TP53 occur later[72]. With the exception of 
GNAS, these driver genes are also commonly found in invasive PDACs occurring in the 
absence of IPMN[73]. Most studies of malignant progression in IPMNs analyzed a 
single tissue section from each lesion across many patients, allowing comparison of the 
genetic alterations among different IPMNs based on grade of dysplasia or other clinical 
and pathological features[15,17,21,24,74]. Although such studies allow estimation of 
mutation prevalence in specific IPMN subgroups, they do not provide comprehensive 
data about the diversity of genetic alterations within a single lesion. Recent studies that 
analyzed more than one section from each IPMN suggest the potential for substantial 
genetic heterogeneity within these neoplasms; however, analyses systematically 
interrogating this genetic heterogeneity are currently lacking. Such studies can provide 




Importantly, recent data have shown a lack of genetic heterogeneity with respect to 
driver gene alterations in invasive PDAC, raising the possibility that unique evolutionary 
processes govern the earlier stages of tumorigenesis in the pancreas[75,76]. As our 
current understanding of pancreatic tumor evolution has mostly been inferred from 
sequencing advanced cancers, there is a critical need for analyses of bona fide 
precancers to directly describe initiation and progression in pancreatic neoplasia. The 
importance of studying precancers has been exemplified in other tumor types, such as 
esophageal carcinogenesis[77,78]. These studies reshaped our understanding of the 
origin and dynamics of tumorigenesis in these organs and have significant biologic and 
therapeutic implications. 
 To explore the evolutionary history of early pancreatic tumorigenesis, we 
performed multi-region targeted next generation sequencing on surgically resected 
IPMNs. These data provide novel insights into IPMN progression, which will advance 
our understanding of the origins of invasive pancreatic cancer. 
Materials and Methods 
Specimen acquisition. This study was approved by the Institutional Review Board of 
the Johns Hopkins Hospital. We retrospectively collected multi-region samples from 20 
patients diagnosed with IPMN who had undergone surgical resection at the Johns 
Hopkins Hospital between 2008 and 2015. Slides from every available formalin-fixed 
paraffin embedded (FFPE) block from each IPMN were stained with hematoxylin-and-
eosin (H&E). An H&E slide from each block was reviewed by an expert pancreatic 




slide from each matched normal (duodenum or spleen) was also reviewed by an expert 
pathologist prior to DNA extraction. 
Laser capture microdissection. Five 10µm serial tissue sections from FFPE blocks 
were cut onto membrane slides (Zeiss MembranSlide 1.0 PEN). Deparaffinization was 
performed in fresh xylenes for 2 min, followed by 100% ethanol for 2 min, 95% ethanol 
for 2 min, and 70% ethanol for 2 min. Subsequently, the slides were stained by crystal-
violet (Sigma Aldrich; diluted 1:4 in 70% ethanol) for 30 sec and dehydrated by 
ascending ethanol solutions. The stained slides were microdissected within 1 h. 
Regions of IPMN epithelium were identified under the microscope and microdissected 
for enrichment of neoplastic cellularity on a Leica LMD7000 instrument. Microdissected 
tissues were collected into 0.5ml Lo-bind tubes (Eppendorf) and immediately processed 
for subsequent DNA extraction. For matched-normal samples, five 5µm sections were 
cut onto regular slides and tissue was scraped off using a sterile razor blade 
(Personna).  
DNA extraction and quantification. DNA was extracted from each sample using the 
QIAamp DNA FFPE Tissue kit (Qiagen) and the MagMAX FFPE Isolation kit (Applied 
Biosystems). Briefly, 180µl ATL buffer and 20µl proteinase K was added to the 0.5ml 
Lo-bind tube containing tissue and subsequently incubated on an agitating thermomixer 
for 24h at 56C. After this period, 2µl of MagMAX protease was added and incubated on 
a stationary heat block for 1h at 60C, followed by incubation for 30min at 80C. Next, 
200µl of AL buffer and 1µg of carrier RNA were added to the sample and incubated for 
20min at 70C. Finally, ethanol precipitation and column elution were conducted using 




concentration was measured using the Qubit dsDNA High Sensitivity Assay kit 
(Invitrogen) according to the manufacturer’s protocol on a Qubit 2.0 fluorometer 
(Invitrogen). DNA was stored at -20C until library preparation. 
Targeted sequencing and analysis. A targeted sequencing approach analyzed the 
entire coding regions of 15 known driver genes in IPMN tumorigenesis (KRAS, GNAS, 
BRAF, RNF43, CDKN2A, PIK3CA, PTEN, APC, CTNNB1, MAP2K4, STK11, ATM, 
TP53, TGFBR2, SMAD4). Library preparation was performed using the Agilent 
SureSelectXT Target Enrichment System (Agilent) following the manufacturer’s 
instructions with the following modifications: genomic DNA was sheared to 200-250bp 
fragments using a Covaris M220 Focused-ultrasonicator (Covaris). Additionally, both 
pre- and post-capture PCR cycle number was increased by 0, 1, or 2 for DNA inputs of 
200ng, 50-100ng, or 25-50ng, respectively. The barcoded libraries were sequenced 
using an Illumina MiSeq system (Illumina), generating 300 base pairs (2x150bp reads) 
per fragment. The average distinct sequencing depth was 570x per sample. Sequence 
alignment files were processed according to Genome Analysis Toolkit (GATK) best 
practices[79,80]. Sequences were aligned using Burrow-Wheeler Aligner (BWA)[81] to 
the human reference genome (UCSC hg19). Duplicate reads were marked with Picard 
Tools[82]. Somatic mutations were identified by processing matched normal and tumor 
reads with MuTect (single nucleotide variants) and MuTect 2 (indels)[83]. We identified 
candidate mutations that were altered in ≥5% of distinct reads with coverage >100X. All 
candidate mutations were confirmed or rejected following visual inspection in Integrated 
Genome Viewer (IGV)[84]. To not over-estimate genetic heterogeneity, every mutation 




other samples to ensure sufficient coverage of >100x - thus, minimizing false negative 
calls. Additionally, previous modeling on the probability of detecting mutations at a given 
depth of coverage ensures an extremely low likelihood of representing false negatives 
given DNA input and coverage[85]. 
Somatic mutation evolutionary reconstruction. We reconstructed somatic mutation 
evolutionary trees based on the neoplastic cell fractions (NCFs) of the mutations we 
identified, using SCHISM software[86]. Mutation NCFs were calculated using VAF, 
estimated tumor purity (p), tumor copy number (CNT) at the mutation site, germline copy 




Tumor purity and copy number are difficult to estimate from a small targeted 
panel. Rather than assuming a single value for purity, on which both CNT and NCF 
depend, we tried purity values in the range 0.5 to 0.9, in increments of 0.1. CNT and m 
were estimated at each purity level. Tumor integer copy number was estimated by 
scaling the tumor-to-normal read ratios to consider purity. In the absence of allele-
specific copy number information, m was set to 1 unless VAF>0.8. For mutations with 
VAF>0.8, m was set to the CNT if CNT ≤ 2, and CNT-1 if CNT >2. 
For each IPMN, SCHISM was used to estimate an optimal evolutionary tree at 
each purity level. We chose the optimal tree based on the highest fitness value 











fitness value, we present all trees in Supplementary Figure 1. If SCHISM could not infer 
a tree with a fitness >0.1, we excluded the case from the evolutionary analysis. SCHISM 
was originally designed to model only tumors of monoclonal origin, and we extended it 
to handle topologies with multiple originating clones. 
Whole-exome sequencing and analysis. Human exome capture was performed using 
Agilent’s SureSelect Human All Exon 50Mb Kit 5.0 (Agilent). The captured libraries were 
sequenced with an Illumina XTEN system, generating 300 base pairs (2x150bp reads) 
per fragment. The average distinct sequencing depth was 104x per sample. After 
Illumina sequencing, all produced FASTQ reads were quality-checked and trimmed with 
FastQC (version 0.11.2) and Trimmomatic (version 0.33)[87]. Sequencing reads were 
aligned to human genome version hg19 with the BWA MEM software for both tumor and 
normal samples[81]. PCR duplications were marked with Picard software (version 
1.103)[82]. The BAM files were locally realigned, and the base quality scores were 
recalibrated with GATK (version 3.1)[79]. MuTect (version 1.1.6) was used to call single 
nucleotide variants with default parameters[83]. Only SNVs that were classified as 
“KEEP” by MuTect and >10% VAF were used for downstream analysis. Indels were 
found using Strelka (version 1.0.14) with default parameters[88].  We identified 
candidate mutations that were altered in ≥10% of distinct reads. All candidate mutations 
were confirmed or rejected following visual inspection in Integrated Genome Viewer 
(IGV)[84]. 
Single-molecule RNA in situ hybridization. The BaseScope assays (Advanced Cell 
Diagnostics, Inc., Newark, CA) were developed to achieve point mutation-specific 




technology[89] in which paired double-Z oligonucleotide probes were designed against 
target RNA using custom software, but BaseScope uses an additional signal 
amplification step and requires only one “double Z” (1 ZZ) probe pair for single-molecule 
detection. The 1-ZZ probe BA-Hs-KRAS-G12V was designed to target KRAS G12V (nt. 
G35T) mRNA, the 1-ZZ probe BA-Hs-KRAS-G12D was designed to target KRAS G12D 
(nt. G35A) mRNA, and the 1-ZZ probe BA-Hs-KRAS-G12R was designed to target 
KRAS G12R (nt. G34C) mRNA. All the above probes were validated using KRAS 
control cell lines (G12V: SW620; G12D: SNU-C2B; G12R: PSN1) for probe specificity. 
The BaseScope™ Reagent Kit – RED (Advanced Cell Diagnostics) was used for 
sample pretreatment, hybridization and signal development according to the 
manufacturer’s instructions. FFPE tissue section samples were prepared according to 
manufacturer’s recommendations. Each FFPE sample was quality controlled for RNA 
integrity with a BaseScope 1-ZZ probe specific to the housekeeping gene Hs-PPIB. 
Negative control background staining was evaluated using a 1-ZZ probe specific to the 
bacterial dapB gene. 
Estimating genetic heterogeneity. Genetic heterogeneity was quantitatively measured 
using Jaccard similarity coefficients. The Jaccard similarity coefficient is defined as the 
ratio of shared variants to all variants (shared + discordant) between two samples. We 
calculated Jaccard similarity coefficients (based on KRAS and GNAS mutations only) 
between all samples for each IPMN. Next, we calculated the average Jaccard similarity 
coefficient for each IPMN. Additionally, the average coefficient of high-grade IPMNs was 
recalculated after excluding low-grade samples. The average Jaccard similarity 




lesion analysis), and high-grade IPMNs (high-grade only analysis)) using ggplot2 
function in R[90] and significant differences between groups were determined by Mann-
Whitney U test.   
Software. OncoPrinter software available through Memorial Sloan Kettering Cancer 
Center’s cBioPortal was used to generate Figure 1. SCHISM software is available for 
non-profit use at https://karchinlab.org/apps/appSchism.html. 
Results 
Clinical and pathological features. This study included 227 neoplastic samples from 
20 surgically resected IPMNs (Table 2.1). Of the 20 IPMNs analyzed, ten had low-grade 
dysplasia and ten had high-grade dysplasia. Of the ten high-grade IPMNs, three had co-
occurring pancreatic ductal adenocarcinoma (PDAC), one of which occurred in the 
same blocks as the IPMN. The size of IPMNs in our cohort ranged from 1.6 cm to 6.5 
cm, resulting in 6 to 24 FFPE blocks per case. For each case, IPMN epithelium was 
microdissected from every FFPE block. Importantly, because IPMNs are classified 
based on the highest grade of dysplasia present in the lesion, high-grade IPMNs will 
often also contain areas with low-grade dysplasia, even in the same FFPE block. 
Therefore, areas of low-grade dysplasia were separately microdissected from the areas 
of high-grade dysplasia. We refer to each FFPE block as an analyzed “region” from 
which we isolated one or two DNA “samples” based on the grade(s) of dysplasia 
present within the FFPE block. Of the ten high-grade IPMNs, seven also contained low-
grade dysplasia – resulting in more total samples than regions in these cases. We 
microdissected a total of 117 low-grade samples, 105 high-grade samples, and five 




overall classified as high-grade. Matched normal DNA for each case from duodenum or 
spleen was also analyzed using the same sequencing pipeline and used as a germline 
comparator. 
Multi-region sequencing reveals striking driver gene heterogeneity in IPMN. 
Targeted next generation sequencing (mean distinct coverage >500x) was used to 
interrogate the entire coding regions of 15 well characterized driver genes in pancreatic 
tumorigenesis. Based on previous literature that characterized these driver gene 
mutations, we consider mutations in KRAS, GNAS, and BRAF to be “early drivers,” 
while we consider mutations in the other genes interrogated by our panel to be “later-
occurring drivers”[17,72,74]. Mutations (including single nucleotide variants and small 
insertions/deletions) were identified in KRAS, GNAS, BRAF, RNF43, CDKN2A, 
PIK3CA, CTNNB1, STK11, ATM, APC, and TP53 (Table 2.1). The total number of 
somatic driver gene mutations called in each analyzed IPMN ranged from 2 to 9 (Table 
2.1). The most commonly mutated genes were KRAS and GNAS – all IPMNs had at 
least one KRAS mutation, and 17 had at least one GNAS mutation (Figures 2.1A and 
2.1B). Of the 20 IPMNs, 15 had multiple mutations called in the same driver gene. 
This sequencing approach identified mutations that were present in all regions of 
an IPMN (hereafter referred to as “homogeneous mutations”), as well as mutations that 
were only present in a subset of the analyzed regions (hereafter referred to as 
“heterogeneous mutations”). On average, a greater proportion of mutations were 
heterogeneous in low-grade IPMNs, relative to high-grade (Figure 2.1C). Of the ten low-
grade IPMNs, three did not contain any homogeneous mutations, and nine contained at 




the molecular features of IPMN epithelium with different grades of dysplasia, we 
analyzed IPMNs classified as high-grade in two different ways: (1) we considered both 
the low-grade and high-grade samples for each IPMN, which we call “whole lesion 
analysis”, and (2) we considered only the high-grade samples, which we call “high-
grade only analysis.” Using whole lesion analysis, 57% of mutations were 
heterogeneous in high-grade IPMNs. However, this proportion decreased to 36% in the 
high-grade only analysis, suggesting that high-grade samples were less heterogeneous 
than low-grade samples within the same IPMN. (Figure 2.1C). For example, IPC15 
appeared to contain only heterogeneous mutations via whole lesion analysis; yet, less 
than half of the mutations were heterogeneous after excluding low-grade samples. 
These data demonstrate a striking degree of driver gene heterogeneity in IPMNs, 
especially those classified as low-grade, indicating that the identification of a driver 
mutation in one region of an IPMN does not necessarily imply its occurrence throughout 
the entire lesion.  
Early driver genetic heterogeneity is pervasive in IPMNs with low-grade 
dysplasia. All of the IPMNs in our cohort harbored mutations in GNAS and/or KRAS, 
and we identified 11 with multiple mutations in these early driver genes. These 11 
IPMNs all had multiple mutations in KRAS, including seven with two different KRAS 
mutations, two with three different KRAS mutations, and two with four different KRAS 
mutations. In every sample that contained multiple KRAS mutations, each mutation was 
found on distinct sequencing reads and therefore did not occur on the same allele. Of 
these 11 IPMNs with multiple KRAS mutations, six also had multiple GNAS mutations. 




GNAS, respectively (Figures 2.1A and 2.1B). Of the ten low-grade IPMNs, seven 
harbored multiple mutations in GNAS and/or KRAS, while this was true for just one 
high-grade IPMN when performing high-grade only analysis (Fisher’s exact test; 
p=0.02). We quantitatively measured genetic heterogeneity with respect to KRAS and 
GNAS by calculating Jaccard similarity coefficients[75,76] (Table 2.2). When using 
whole lesion analysis, we found that low-grade IPMNs were more genetically 
heterogeneous than high-grade IPMNs with respect to KRAS and GNAS (0.63 v. 0.87; 
Mann-Whitney U test, p=0.070). Moreover, when using high-grade only analysis, high-
grade IPMNs were significantly less genetically heterogeneous that low-grade IPMNs 
with respect to these early driver gene alterations (0.63 v. 0.92; Mann-Whitney U test, 
p=0.019) (Figure 2.2A). Altogether, these data reveal genetic heterogeneity with respect 
to early drivers is significantly more prevalent in low-grade IPMNs. 
Evolutionary modeling suggests polyclonal origin of early pancreatic 
tumorigenesis. Evolutionary trees, built with SCHISM[86] (see Methods), suggested 
that several IPMNs were polyclonal in origin – having initiated from more than one 
separate and independent clone (Figure 2.2). For example, we identified three different 
KRAS mutations (KRAS p.G12D, p.G12R, p.G12V) in IPC03, each marking a distinct 
clone (Figure 2.2B). In another example, whole lesion analysis of IPC15 inferred it 
originated from three clones, each marked by a different early driver (KRAS p.G12V, 
KRAS p.G12D, GNAS p.R201C) (Figure 2.2C). Interestingly, the clone containing KRAS 
p.G12D and GNAS p.R201S was absent in the high-grade samples, demonstrating this 
clone was limited to the low-grade dysplasia. Strikingly, whole lesion analysis of IPC14 




p.G12R mutation – however, high-grade only analysis revealed that the high-grade 
neoplasia in IPC14 initiated from a single clone (GNAS p.R201H) (Figure 2.2D). 
Altogether, some high-grade IPMNs appear polyclonal in origin, but IPC15 is the only 
high-grade IPMN that retains polyclonality after excluding low-grade samples from the 
analysis. 
Whole exome sequencing confirms independent origin of clones with discordant 
mutations in early driver genes. While our targeted sequencing data coupled with 
evolutionary modeling suggests polyclonal origin for several IPMNs in our cohort, it is 
also possible that these multiple KRAS mutations occurred as divergent later events in 
a monoclonal IPMN initiated by an alteration not examined by our targeted panel. In 
order to more definitively characterize the clonal origin of the analyzed IPMNs, we 
performed whole exome sequencing (WES) on two regions each from four IPMNs 
(IPC01, IPC08, IPC12, and IPC14). For each IPMN analyzed by WES, we chose two 
regions with mutually exclusive early driver gene mutations based on our targeted 
sequencing. For example, samples T5 HG and T8 LG from IPC14 were chosen for 
WES because T5 HG had a GNAS p.R201H mutation, while T8 LG had a KRAS 
p.G12R and BRAF p.E26D (Figure 2.2D). On average, we found ~30 coding somatic 
mutations per IPMN region and, importantly, we did not identify any shared alterations 
between the two regions (Tables 2.3-2.6). Additionally, all mutations called using our 
targeted sequencing approach at >10% VAF were also found via WES at similar 
frequencies, further validating the accuracy of our multi-region targeted sequencing. 
Overall, this comprehensive approach has corroborated our evolutionary modeling and 




first time, strong evidence for polyclonal origin of these neoplasms. If these results are 
extrapolated to all IPMNs in our cohort harboring multiple early driver gene mutations, 
this suggests 60% of the analyzed IPMNs are polyclonal in origin.  
RNA in-situ hybridization confirms spatial separation of mutant KRAS subclones. 
The targeted sequencing and evolutionary modeling in the current study suggest that 
multiple KRAS mutations observed within a single IPMN occurred in different clones; 
however, these data cannot resolve whether the cells containing discordant KRAS 
mutations are intermixed or spatially separated. To determine the spatial location of 
cells with discordant KRAS mutations we employed BaseScope, which uses RNA in situ 
hybridization to specifically detect hotspot alterations in KRAS (see Methods). We 
analyzed one region each from five IPMNs by probing for KRAS p.G12V, p.G12D, and 
p.G12R, which were validated using KRAS mutant cell lines. We chose regions to 
analyze based on several factors, including age of tissue block, amount of IPMN 
epithelium within block, and identification of KRAS mutations targeted by BaseScope 
probes. Interestingly, in each region that contained multiple KRAS mutations, we 
identified clones that were spatially separated (Figure 2.3, representative case). For 
example, IPC09 B was a low-grade region with three distinct areas of IPMN epithelium, 
which were pooled for sequencing (Figure 2.3A). Targeted sequencing indicated the 
neoplastic cells in this region had KRAS p.G12D and p.G12V mutations. The IPMN cells 
in areas 1 and 2 expressed KRAS p.G12D, but not p.G12V (Figures 2.3B-2.3E). 
Conversely, the IPMN cells in area 3 expressed KRAS p.G12V, but not p.G12D (Figure 
2.3F and 2.3G). Overall, while areas 1 and 2 were spatially separated, they expressed 




was spatially separated from areas 1 and 2 and expressed a different KRAS mutation, 
suggesting this region likely originated from a distinct clone (Figure 2.3H). Importantly, 
the results of the BaseScope assay for each analyzed IPMN region were concordant 
with our targeted sequencing with respect to the KRAS mutations identified and the 
relative proportions of cells containing each mutation. 
Convergent evolution and heterogeneity of later-occurring driver genes in IPMNs 
with high-grade dysplasia. In addition to heterogeneity with respect to early driver 
gene mutations, we also identified genetic heterogeneity with respect to later-occurring 
driver gene mutations in several IPMNs in our cohort. Multiple RNF43 mutations were 
identified in five IPMNs from our cohort. Four IPMNs (IPC07, IPC18, IPC19, and IPC20) 
had two different RNF43 mutations, while IPC16 had four different RNF43 mutations 
(Figure 2.4A). The four RNF43 mutations identified in IPC16 were either nonsense or 
frameshift and interestingly, all four were identified in distinct regions. One RNF43 
mutation (p.R49Sfs*3) was present in both the low-grade and high-grade dysplasia from 
a single region. A second RNF43 mutation (p.R132*) was only found in a different 
region with low-grade dysplasia. The remaining two RNF43 mutations (p.Q152*and 
T76Nfs*13) were found in separate regions with only high-grade dysplasia. These data 
demonstrate multiple, distinct mutations occurring in the RNF43 gene, suggesting there 
is a specific selection for these mutations in a subset of IPMNs. We also observed 
multiple mutations in the TP53 gene. One high-grade IPMN (IPC20) had four different 
TP53 mutations (Figure 2.4B). One TP53 missense mutation (p.V172D) was present in 
every region, while the other TP53 missense mutations (p.P152L, p.D208A, and 




While our data suggest low-grade IPMNs are significantly more heterogeneous 
with respect to early driver mutations, heterogeneity amongst later-occurring driver 
mutations is prominent in high-grade IPMNs. Of the five IPMNs harboring multiple 
RNF43 mutations, four were high-grade IPMNs. Interestingly, while early driver 
heterogeneity was less prevalent in high-grade IPMNs relative to low-grade, this was 
not true for later-occurring drivers (Figure 2.4C and 2.4D). Heterogeneity with respect to 
these later-occurring driver mutations seems to be a feature of high-grade IPMNs.  
Mutations in less commonly mutated driver genes also occurred in our cohort. 
Four IPMNs (IPC06, IPC08, IPC14, and IPC17) had mutations in BRAF. IPMNs IPC06 
and IPC08 had the same in-frame deletion of BRAF (p.N486_P490del), which has 
previously been reported in IPMNs and numerous other cancers[91,92] and, 
interestingly, has been shown to confer sensitivity to BRAF inhibitors[93]. In IPC08, we 
identified two regions which lacked a KRAS mutation, yet harbored this BRAF deletion 
(Figure 2.1). Two IPMNs (IPC03 and IPC17) had missense mutations in CDKN2A. Two 
IPMNs (IPC07 and IPC09) had mutations in oncogenic hotspots of PIK3CA (p.N1044K 
and p.H1047R). In IPC09, every region harbored PIK3CA p.H1047R and KRAS p.G12V 
at similar NCF; therefore, we could not determine which mutation occurred first, or if 
these mutations represent distinct clones. One IPMN (IPC06) had a mutation in an 
oncogenic hotspot of CTNNB1, and one IPMN (IPC19) had a missense APC mutation. 
One IPMN (IPC10) had a missense mutation in STK11. Three IPMNs (IPC08, IPC12, 
and IPC14) had mutations in ATM, one of which (IPC12) was an inactivating frameshift 




Clinical implications of genetic heterogeneity in IPMN. An independent study 
analyzed somatic mutations in cyst fluid from patients diagnosed with IPMN prior to 
surgical resection (manuscript under review). Seven cases from this study overlapped 
with our cohort (IPC03, IPC04, IPC06, IPC08, IPC12, IPC18, and IPC20). We 
compared driver gene mutations identified in DNA collected from cyst fluid to our multi-
region targeted sequencing. For all cases, mutations found in the cyst fluid were also 
found via our multi-region sequencing approach except for those at very low VAF in the 
cyst fluid analysis (range 0.00076-0.034 VAF). In all cases, there were mutations 
identified by our multi-region sequencing approach that were not identified in the cyst 
fluid. For example, both approaches found KRAS p.G12V in IPC03; yet, two additional 
KRAS mutations (p.G12D and p.G12R), and a GNAS mutation (p.R201H) were not 
identified in the cyst fluid analysis (Table 2.7). In general, the mutations not identified in 
the cyst fluid were present in only a subset of regions within a given IPMN. 
Discussion 
Because IPMNs are often diagnosed on imaging studies, they can be resected 
prior to the development of invasive PDAC – as such, IPMNs represent an ideal system 
in which to perform comprehensive analyses of precancerous pancreatic neoplasia. In 
this study, we performed multi-region targeted sequencing on 227 neoplastic samples 
from 20 IPMNs, using meticulous isolation of epithelium via LCM from 6 to 24 regions 
per IPMN. Thus, our study represents one of the most comprehensive genetic analyses 
of driver gene mutations in IPMNs to date, and to our knowledge, the only study to 




suggest that these precancers are derived from multiple independent clones, 
transforming our understanding of the origins of pancreatic tumorigenesis. 
Previous studies characterizing the genetic alterations that drive the progression 
of IPMN have typically analyzed a single area from each neoplasm. However, a single 
area may not harbor the full diversity of driver gene alterations within a single IPMN. 
More recent studies have suggested the potential for significant genetic heterogeneity in 
IPMNs – however, these studies did not comprehensively identify the genetic alterations 
across an entire IPMN[19,22]. Here, we demonstrate that the vast majority of analyzed 
IPMNs harbor multiple mutations within the same driver gene. In addition, we report that 
many IPMNs do not have any homogeneous mutations across the entire lesion, 
demonstrating that single-region sequencing approaches are not adequate to accurately 
identify the complete repertoire of driver gene mutations within an IPMN. Furthermore, 
the genes that harbor multiple mutations in IPMNs differ depending on the grade of 
dysplasia and thus the stage of neoplastic progression. We found IPMNs with low-grade 
dysplasia have significantly more heterogeneity with respect to the early drivers KRAS 
and GNAS, compared to IPMNs with high-grade dysplasia. These data demonstrate 
that early pancreatic tumorigenesis is characterized by heterogeneity in initiating driver 
genes, while progression to high-grade dysplasia leads to decreased heterogeneity in 
these early driver genes. This likely represents selection and expansion of a single 
clone after acquisition of additional driver gene alterations, thus eliminating prior clonal 
diversity. This finding is consistent with previous studies which have demonstrated a 




suggesting that this heterogeneity and clonal selection are limited to precancerous 
pancreatic neoplasms.  
Using our multi-region sequencing approach, coupled with evolutionary 
modeling, we show that a substantial proportion of IPMNs in our study evolved from 
multiple distinct clones. This polyclonal origin is typically marked by multiple KRAS 
mutations, yet clones can also originate from GNAS mutations, albeit less frequently. 
Intriguingly, one of the analyzed IPMNs harbored two independent clones, one initiated 
by a mutation in KRAS and one by a mutation in GNAS. This demonstrates that 
independent clones can be initiated by mutations in different genes, suggesting that the 
presence of multiple mutations in a single early driver gene probably underestimates 
polyclonality. Importantly, WES of IPMN regions with discordant early driver mutations 
did not identify any shared mutations across the entire exome, further demonstrating 
their independent clonal origin. We also used in situ mutation detection to demonstrate 
that distinct KRAS mutations within a single IPMN regions are spatially separate.  
Interestingly, a previous study by The Cancer Genome Atlas used computational 
analyses to suggest that multiple KRAS mutations occurred in the same cells in invasive 
PDACs[94]. The discordant results between these two studies reveal a potential 
difference between pancreatic precancerous lesions and advanced cancers and 
highlight the importance of directly measuring individual single-cell genotypes.  
Taken together, these data support a revised model of early pancreatic 
tumorigenesis in which some IPMNs originate from multiple clones that evolve 
independently, one of which may acquire additional driver gene mutations that lead to 




from multiple independent clones, our WES data did not identify a single shared 
mutation preceding KRAS, suggesting that there is not an earlier coding genetic event 
initiating these lesions. Moreover, there were no shared passenger alterations in these 
distinct sections. Because a subset of such passenger alterations accumulate prior to 
tumor development, the lack of shared passenger mutations suggests that the different 
clones arose from completely separate cells[95].  
In addition to multiple mutations in early driver genes, we also identified multiple 
mutations in later-occurring driver genes in the same IPMN. We identified five IPMNs 
harboring multiple RNF43 mutations, which were often located in different regions. We 
also identified one IPMN containing four different TP53 mutations. Nearly all of the 
IPMNs with multiple mutations in TP53 and/or RNF43 had high-grade dysplasia, 
suggesting heterogeneity with respect to later-occurring driver gene mutations may be a 
feature of IPMNs with greater malignant potential. These data add to our revised 
tumorigenesis model – following the selective sweep and fixation of a dominant clone, 
additional mutations arise in later-occurring drivers, often multiple mutations in the same 
gene (Figure 2.5). Similar evidence for convergent evolution has been reported in other 
tumor types, including colorectal and clear cell renal carcinoma[96,97]. The selective 
forces that lead to convergence of multiple mutations in the same gene are not known. 
Further investigation into the conditions that select for multiple mutations within specific 
genes may provide novel insights into later stages of IPMN progression, as well as the 
functional outcomes of specific driver gene alterations.  
Many studies have demonstrated the value of analyzing cyst fluid collected by 




pancreatic cysts. Several reports highlight the diagnostic value of molecular markers in 
cyst fluid for differentiating likely benign cysts from those which have greater risk of 
malignant progression[62,63,98]. Integration of our multi-region sequencing data with 
cyst fluid molecular analysis on a subset of patients in our cohort reveals important 
clinical implications for interpreting such molecular biomarkers. Not all driver gene 
mutations within an IPMN may be captured by cyst fluid analysis, even with high-depth 
sequencing strategies. Because most of the mutations not identified in cyst fluid were 
present focally in one or a few regions of the IPMN, it is likely that the genetic material 
containing these mutations was not present in the cyst fluid. These findings highlight the 
potential challenges with IPMN risk stratification. 
There are some limitations to our study. First, while our study encompassed a 
large cohort of 227 neoplastic tissue samples, these represent only 20 IPMNs. In this 
study, we prioritized comprehensive analysis of the entire IPMN but could only perform 
such in-depth analysis on a limited number of IPMN lesions that were entirely submitted 
for histologic examination. As such, our findings will need to be confirmed in larger 
IPMN cohorts. Nevertheless, this case size was still sufficient to detect statistically 
significant differences in genetic heterogeneity between IPMNs with different grades of 
dysplasia. Second, the majority of samples were sequenced using a small targeted 
panel of 15 pancreatic driver genes. The use of such a focused sequencing approach 
allowed us to analyze a large number of samples at high sequencing depth, and thus 
confidently report the most biologically important driver gene mutations even when they 
were subclonal. Our sequencing strategy was not designed to provide sufficient data to 




definitively resolving the evolutionary history of every IPMN. Heterogeneity and 
evolutionary insights that integrate these types of genetic alterations will require 
additional studies. Third, our cohort of low-grade and high-grade IPMNs does not have 
a balanced distribution of histological subtypes, with the gastric histologic subtype 
enriched in low-grade IPMNs and intestinal and pancreatobiliary subtypes enriched in 
high-grade IPMNs. However, histologic subtype is not independent of grade of 
dysplasia, with the vast majority of surgically resected low-grade IPMNs having gastric-
type epithelium[99]. Thus, the distribution of histological subtypes in our cohort is 
representative of low-grade and high-grade IPMNs. Larger studies of genetic 
heterogeneity specifically focused on histologic subtype may reveal additional insights. 
Finally, our experimental design required the analysis of surgically resected IPMNs. 
Because only a small fraction of IPMNs identified radiologically are eventually resected, 
and the decision to resect is based on specific clinical and radiological criteria[100], our 
cohort is not representative of the entire spectrum of IPMNs in the population. It is 
possible that enrichment for larger IPMNs in our resected cohort may also enrich for 
polyclonality. Analysis of low-grade IPMNs that were not targeted for surgical resection 
(either through autopsy studies or IPMNs resected along with other neoplasms) will be 
required to investigate this. 
In conclusion, using IPMNs as a system in which to analyze early pancreatic 
neoplasia, our data provide several insights into the acquisition of somatic mutations 
during pancreatic tumorigenesis. We show that genetic heterogeneity with respect to 
driver gene alterations is pervasive in IPMNs. Heterogeneity of the early drivers KRAS 




KRAS mutations marking multiple independent clones arising from separate cells. In 
addition, convergent evolution with respect to later-occurring driver gene mutations is 
present in high-grade IPMNs, demonstrating unique selective pressures at different 
stages of tumor progression. The results of this study challenge the traditional 
monoclonal origin of pancreatic tumors, highlighting distinct evolutionary features of 
precancerous lesions and transforming our understanding of the clonal evolution of 
pancreatic neoplasia. Future studies will focus on other types of precancerous lesions in 



























# of samples 
(LGD,HGD,PDAC) 
Mutations Identified 
IPC01 F 80 Head 1.6 Gastric IPMN with LGD IPMN 6 6           (6,0,0) 
KRAS(p.G12D, p.G12R, p.G12V, p.GQ60GK), 
RNF43(p.A169T) 
IPC02 M 50 Tail 4.5 Gastric IPMN with LGD IPMN 8 8           (8,0,0) 
KRAS(p.G12D, p.G12R, p.G12V), GNAS(p.R201C, 
p.R201H), RNF43(p.R286W), TP53(p.P72R) 
IPC03 F 60 Tail 2.3 Gastric IPMN with LGD IPMN 6 6           (6,0,0) 
KRAS(p.G12D, p.G12R, p.G12V), GNAS(p.R201H), 
CDKN2A(p.R80P) 
IPC04 M 70 Head 4.2 Gastric IPMN with LGD IPMN 6 6           (6,0,0) KRAS(p.G12R), GNAS(p.R201H) 
IPC05 F 80 Tail 2.8 Gastric IPMN with LGD IPMN 8 8           (8,0,0) KRAS(p.G12V), GNAS(p.R201C) 




IPC07 M 60 Head 5 Gastric IPMN with LGD IPMN 11 11       (11,0,0) 
KRAS(p.G12D, p.G12V), GNAS(p.R201C), 
RNF43(p.W15*, p.A115Pfs*43), PIK3CA(p.N1044K) 
IPC08 F 70 Head 3 Gastric IPMN with LGD IPMN 8 8           (8,0,0) 
KRAS(p.G12D, p.G12R, p.G12V, p.A146V), 
GNAS(p.R201C, p.Q227H), RNF43(p.P231L), 
BRAF(p.N486_P490del), ATM(p.P1526P) 
IPC09 M 80 Tail 3 Intestinal IPMN with LGD IPMN 7 7           (7,0,0) KRAS(p.G12D, p.G12V), PIK3CA(p.H1047R) 
IPC10 M 70 Head 3 Gastric IPMN with LGD IPMN 6 6           (6,0,0) 
KRAS(p.G12D, p.G12V), GNAS(p.R201C, p.R201H), 
RNF43(p.L418M), STK11(p.P203S) 
IPC11 M 70 Head 5 Pancreatobiliary IPMN with HGD IPMN 10 13         (6,7,0) 
KRAS(p.G12V, p.G12S), GNAS(p.R201C, p.R201H, 
p.Q227E) 
IPC12 F 90 Head 5.5 Intestinal IPMN with HGD IPMN 23 25       (3,22,0) 
KRAS(p.A146V, p.Q61H), GNAS(p.R201C, p.Q227H), 
RNF43(p.Q6Rfs*9), ATM(p.L2475Yfs*2), TP53(p.P72R) 






22 25       (0,20,5) KRAS(p.G12D), GNAS(p.R201H) 




IPMN 11 12         (5,7,0) 
KRAS(p.G12R), GNAS(p.R201H), BRAF(p.E26D), 
ATM(p.L1517F) 
IPC15 M 70 Head 3 Pancreatobiliary IPMN with HGD IPMN 8 9           (5,4,0) 
KRAS(p.G12D, p.G12V), GNAS(p.R201C, p.R201S), 
RNF43(p.E37*) 
IPC16 F 70 Tail 2.4 Intestinal IPMN with HGD IPMN 6 10         (7,3,0) 
KRAS(p.G12D), GNAS(p.R201H), RNF43(p.R49Sfs*3, 
p.R132*, p.Q152*, p.T76Nfs*13) 
IPC17 M 80 Head 5 Intestinal IPMN with HGD IPMN 18 19       (15,4,0) 
KRAS(p.A146T, p.Q61H), GNAS(p.R201C), 
RNF43(p.C119Lfs*6), BRAF(p.T241M), 
CDKN2A(p.H83N) 
IPC18 M 60 Head 4 Pancreatobiliary IPMN with HGD IPMN 8 9           (1,8,0) KRAS(p.G12V), RNF43(p.A115Pfs*43, p.S216L) 
IPC19 M 70 Head 4 Intestinal IPMN with HGD IPMN 6 6           (0,6,0) 
KRAS(p.G12D), GNAS(p.R201H), RNF43(p.A169T, 
p.R337*), APC(p.R99W) 




IPMN 24 24       (0,24,0) 
KRAS(p.G13D), GNAS(p.R201C), RNF43(p.I141N, 
p.I201N), TP53(p.V172D, p.P152L, p.D208A, p.R248Q) 
*To ensure patient privacy, age (at surgery) was rounded in the nearest decade 























Figure 2.1. Landscape of somatic driver gene mutations in IPMNs. Integrated genomic data for 227 samples (bars) from 20 IPMNs (columns). The histologic 
subtype and grade of dysplasia data for each sample are shown as tracks at the top. IPMNs are grouped by grade of dysplasia with low-grade on the left and high-
grade on the right. A. Bar plot representing the total number of KRAS and GNAS mutations per sample. B. Oncoprint heatmap depicting mutations occurring in 
KRAS, GNAS, or others (see color legend) or absence (gray bar). Single-nucleotide variants are listed for KRAS and GNAS, all other mutations are grouped by 
gene (rows). The percentage of samples with a given mutation is noted at the left. C. Proportion of heterogeneous mutations (green) and homogeneous mutations 





Table 2.2. Average Jaccard Similarity Coefficient for Each IPMN Based on KRAS and GNAS 
Mutations 
 
  Average Jaccard Similarity Coefficient 
Case Whole Lesion Analysis High-Grade Only Analysis 
IPC01 0.26   
IPC02 0.85   
IPC03 0.38   
IPC04 0.7   
IPC05 1   
IPC06 0.89   
IPC07 0.9   
IPC08 0.28   
IPC09 0.86   
IPC10 0.19   
IPC11 0.74 0.71 
IPC12 0.89 1 
IPC13 1 1 
IPC14 0.83 1 
IPC15 0.42 0.75 
IPC16 1 1 
IPC17 0.85 0.75 
IPC18 1 1 
IPC19 1 1 
































Figure 2.2. Early driver gene heterogeneity and polyclonal origin of IPMNs. A. Dot plot of the average Jaccard 
similarity coefficient for each case based on KRAS and GNAS mutations only. Low-grade IPMNs are significantly more 
heterogeneous than high-grade IPMNs via whole lesion analysis (p value = 0.070; Mann-Whitney U test) and high-grade 
IPMNs via high-grade only analysis (p value = 0.019; Mann-Whitney U test). B-D. Neoplastic cancer cell fractions (NCFs) 
are presented in heat maps with each row representing a mutation and each column representing a region or sample. 
Each NCF heat map corresponds to a schematic of tumor evolution – SCHISM was used to reconstruct somatic mutation 
hierarchy trees. B. Low-grade IPMN, IPC03. C. Whole lesion analysis (left) or high-grade only analysis (right) of IPC15. D. 




































PRKACA p.D76N 19 14217583 C T 39 0.03 119 0.21 209 0.00
CAD p.A298S 2 27446513 G T 16 0.00 49 0.12 102 0.00
ABCA13 p.R3914I 7 48431604 G T 50 0.00 48 0.15 121 0.00
FRRS1 p.T348I 1 100185167 G A 48 0.00 76 0.28 113 0.00
KRAS p.G12R 12 25398285 C G 79 0.00 94 0.27 169 0.00
TAF2 p.F979Lfs20* 8 120759116 A - 125 0.00 145 0.25 149 0.00
FAM161A p.N201S 2 62067537 T C 85 0.00 122 0.24 156 0.00
MYO5A p.R872* 15 52664524 G A 23 0.00 35 0.23 62 0.00
ASNS p.E461_P466del 7 97482450 TGGTCGCCAGAGAATCTC - 75 0.00 81 0.22 61 0.00
BASP1 p.A203Qfs21* 5 17275928 C - 83 0.00 196 0.21 146 0.00
ZNF354B p.H400R 5 178310652 A G 53 0.00 51 0.21 134 0.00
KDM6A p.A1230D X 44949128 C A 104 0.01 115 0.18 213 0.02
ESPN p.A466E 1 6505928 C A 13 0.00 65 0.16 130 0.00
TIAM1 p.V875M 21 32559356 C T 112 0.01 269 0.00 130 0.19
SDK1 p.T574M 7 4011104 C T 13 0.00 43 0.00 24 0.17
CENPE p.T955A 4 104079782 T C 41 0.00 86 0.00 23 0.52
CASKIN2 p.F982L 17 73498209 G T 13 0.00 126 0.00 53 0.43
AMPH p.D655V 7 38429421 T A 96 0.00 185 0.00 96 0.35
FGF23 p.R196Q 12 4479678 C T 22 0.00 75 0.00 37 0.25
ZNF831 p.P489L 20 57767540 C T 45 0.00 285 0.00 125 0.23
ZMYND8 p.W1187G 20 45839414 A C 53 0.00 218 0.00 93 0.20
TXNRD1 p.T429N 12 104728100 C A 18 0.00 34 0.00 22 0.18
GATAD2A p.R324C 19 19606981 C T 45 0.00 185 0.00 100 0.17
ZNF117 p.H99R 7 64439653 T C 19 0.00 33 0.00 30 0.17
NFKBIB p.G279C 19 39398165 G T 16 0.00 111 0.00 40 0.13
WBSCR17 p.R470L 7 71142200 G T 15 0.00 68 0.00 32 0.13
A2ML1 p.T947K 12 9008180 C A 31 0.00 100 0.00 49 0.13
MSH5 p.A349V 6 31725973 C T 24 0.00 117 0.00 49 0.11
PCDHGA1 p.E561* 5 140711932 G T 28 0.00 92 0.00 42 0.10
SBNO1 p.N1100K 12 123794396 G T 19 0.00 62 0.00 42 0.10




































ZFP36L2 p.F214L 2 43452301 G T 23 0.04 83 0.35 177 0.00
OPHN1 p.H513Q X 67316859 G T 10 0.00 24 0.17 50 0.00
SPTBN2 p.L1779I 11 66458985 G T 10 0.00 35 0.11 94 0.00
TTC8 p.E344* 14 89337993 G T 24 0.00 52 0.37 103 0.00
CSMD3 p.R1041K 8 113662461 C T 34 0.00 77 0.36 106 0.00
TRIM41 p.R450C 5 180661230 C T 20 0.00 47 0.17 116 0.00
KCNN1 p.V273F 19 18092836 G T 11 0.00 39 0.10 140 0.00
NEB p.N6001Y 2 152423837 T A 55 0.00 97 0.50 186 0.00
FASTKD5 p.A98T 20 3129425 C T 35 0.00 74 0.47 167 0.00
ZFHX4 p.S565R 8 77618016 A C 14 0.00 48 0.46 97 0.00
RGAG4 p.E516Q X 71349845 C G 26 0.00 62 0.42 169 0.00
KRAS p.G12V 12 25398284 C A 48 0.00 58 0.35 184 0.00
ATR p.P2188S 3 142186901 G A 17 0.00 16 0.25 59 0.00
LRRC3C p.S75P 17 38100382 T C 11 0.00 30 0.21 80 0.00
SERPINA7 p.V367F X 105277640 C A 14 0.00 26 0.19 48 0.00
C12orf5 p.E19D 12 4440470 G T 24 0.00 34 0.15 74 0.00
MSH4 p.A437S 1 76342624 G T 17 0.00 40 0.13 30 0.00
SVEP1 p.A2926S 9 113169104 C A 20 0.00 42 0.12 82 0.00
KRTAP26-1 p.D28Y 21 31692272 C A 19 0.00 33 0.12 83 0.00
BEND2 p.R210I X 18221899 C A 20 0.00 43 0.12 105 0.00
MYL6B p.E116D 12 56549204 G T 24 0.00 41 0.12 94 0.03
PANK4 p.V577F 1 2443121 C A 23 0.00 45 0.11 87 0.00
SCAPER p.K985N 15 76763676 C A 30 0.00 38 0.11 116 0.02
MLLT4 p.S238R 6 168276153 C A 29 0.00 39 0.10 122 0.00
SRCAP p.Y621* 16 30723630 C A 14 0.00 50 0.10 112 0.00
IRS4 p.A223V X 107978907 G A 10 0.00 42 0.10 102 0.00
DNAJB13 p.P33Q 11 73669391 C A 21 0.00 92 0.00 63 0.27
OR1E2 p.M85I 17 3336881 C A 19 0.00 43 0.00 30 0.17
RIOK3 p.A337E 18 21053587 C A 13 0.00 41 0.00 30 0.17
C4BPA p.Y104H 1 207287612 T C 20 0.00 60 0.00 41 0.15
ATP10D p.P88Q 4 47514820 C A 14 0.00 71 0.00 41 0.15
KIAA1549 p.S1801* 7 138529112 G T 22 0.00 48 0.00 38 0.14
KHDC1 p.A205S 6 73951353 C A 10 0.00 37 0.00 30 0.13
RRN3 p.S548L 16 15159139 G A 59 0.00 157 0.00 132 0.13
FLT3 p.T255I 13 28623890 G A 18 0.00 61 0.00 35 0.11
SRGAP2 p.V150I 1 206566903 G A 34 0.00 133 0.02 63 0.11
ATR p.D883Y 3 142272227 C A 50 0.00 122 0.00 70 0.10






































ZSWIM6 p.Q7* 5 60628118 C T 13 0.00 23 0.39 36 0.00
HHIPL2 p.V694I 1 222696038 C T 64 0.02 89 0.21 101 0.00
ANO2 p.S724* 12 5708727 G T 51 0.02 60 0.10 64 0.00
PNMA3 p.R389G X 152226577 A G 21 0.00 44 0.37 74 0.00
PSD2 p.A55V 5 139189189 C T 27 0.00 38 0.16 75 0.00
BLM p.A3V 15 91290630 C T 40 0.00 54 0.13 97 0.00
GTF3C3 p.R819H 2 197631371 C T 91 0.01 72 0.13 96 0.00
TAF5 p.S765L 10 105147871 C T 157 0.01 172 0.37 222 0.00
GNAS p.R201C 20 57484420 C T 91 0.00 133 0.63 175 0.02
KRAS p.A146V 12 25378561 G A 53 0.00 56 0.61 79 0.00
KIAA1462 p.A990V 10 30316108 G A 49 0.04 37 0.60 83 0.02
INPPL1 p.L806H 11 71946161 T A 27 0.00 20 0.55 50 0.00
OBSCN p.A6815T 1 228528464 G A 39 0.03 67 0.51 95 0.00
SYNE1 p.V172M 6 152831395 C T 40 0.00 45 0.49 57 0.00
ESYT3 p.R309S 3 138183198 A C 28 0.00 41 0.49 53 0.00
ITSN2 p.I1518M 2 24432010 A C 24 0.00 29 0.48 43 0.00
CDH1 p.I326L 16 68845730 A C 38 0.00 41 0.46 73 0.00
TBATA p.R54Q 10 72541673 C T 41 0.05 57 0.44 118 0.01
FOXA3 p.F171S 19 46375775 T C 26 0.00 66 0.42 72 0.00
HSCB p.S117P 22 29140618 T C 87 0.00 87 0.42 142 0.00
RNF43 p.Q6Rfs9* 17 56492913 AGCTGCAGCT - 117 0.00 70 0.40 58 0.00
RHOBTB3 . 5 95124448 TTTTCATTTTTCTTGCAGT - 330 0.00 268 0.39 222 0.00
GRIN2A p.V617M 16 9923438 C T 75 0.00 75 0.37 90 0.00
KIRREL p.A166T 1 158054355 G A 37 0.03 43 0.37 61 0.00
PLEKHG3 p.E443D 14 65205552 G T 16 0.00 46 0.36 71 0.00
PAX3 p.A410V 2 223066851 G A 51 0.02 44 0.34 36 0.00
IGKV3-11 p.I78V 2 89326781 T C 26 0.00 22 0.33 28 0.00
KIAA0947 p.L1752R 5 5464702 T G 54 0.00 54 0.32 79 0.00
HEPH p.C801* X 65423369 C A 58 0.00 55 0.29 47 0.00
SLC22A23 p.E590A 6 3273581 T G 43 0.00 86 0.25 87 0.00
LPIN3 p.I438V 20 39980809 A G 63 0.00 140 0.22 175 0.00
ARMC3 . 10 23257419 G A 28 0.04 19 0.21 12 0.00
DENND4C p.I1595Hfs3* 9 19357115 - T 282 0.00 349 0.21 259 0.00
GLYATL2 p.F256C 11 58602020 A C 33 0.00 25 0.20 43 0.00
DCTN2 p.M1? 12 57940846 T A 15 0.00 23 0.17 17 0.00
C3orf84 p.D59N 3 49215938 C T 19 0.00 34 0.12 31 0.00
RNFT2 p.R416H 12 117287165 G A 32 0.00 68 0.12 61 0.00
MAGEA1 p.A162V X 152482526 G A 80 0.01 108 0.11 174 0.00
SPTAN1 p.R2303H 9 131394566 G A 15 0.00 41 0.10 65 0.00
GNAS p.Q227H 20 57484597 G C 50 0.00 138 0.00 69 0.26
ITGA2 p.D501Y 5 52358658 G T 170 0.01 301 0.00 160 0.20
KRAS p.Q61H 12 25380275 T G 60 0.00 123 0.00 50 0.26
ZW10 p.L375V 11 113618402 G C 66 0.00 95 0.00 46 0.24
RASSF6 p.L60V 4 74464419 A C 52 0.00 107 0.00 47 0.22
JAK2 p.W157* 9 5050687 G A 142 0.00 268 0.00 100 0.19
ACVR1B p.N381T 12 52379015 A C 41 0.00 131 0.00 44 0.18
RND2 p.R54C 17 41178034 C T 16 0.00 81 0.00 30 0.17
AKT3 p.E84K 1 243828108 C T 31 0.00 103 0.00 52 0.15
ZNF573 p.T193K 19 38230813 G T 34 0.00 52 0.00 43 0.14
OPLAH p.K92N 8 145114589 C A 18 0.00 63 0.00 46 0.11
BDH1 p.N168Y 3 197241195 T A 99 0.00 284 0.00 81 0.10




Table 2.6. Summary of Somatic Mutations Identified by Whole Exome Sequencing in IPC14










CEACAM16 p.A196S 19 45207491 G T 14 0.00 34 0.21 51 0.00
GNAS p.R201H 20 57484421 G A 70 0.00 154 0.50 190 0.00
HCFC1 p.E1783K X 153217072 C T 34 0.00 64 0.11 99 0.00
FAM189B p.V157I 1 155223694 C T 49 0.00 121 0.20 208 0.00
HIST1H1B p.A179T 6 27834773 C T 109 0.01 131 0.15 187 0.00
ZBED2 p.R4Q 3 111313038 C T 68 0.02 113 0.10 214 0.00
ACACB p.L1398Pfs26* 12 109671606 T - 246 0.00 293 0.60 364 0.00
UBE2NL p.M1N X 142967203 A G 19 0.00 36 0.78 31 0.00
ZBTB21 p.P436L 21 43412898 G A 37 0.00 41 0.60 93 0.00
SMARCB1 p.T357Dfs4* 22 24175838 - T 42 0.00 79 0.48 135 0.00
ESRP2 p.P125A 16 68267965 G C 32 0.00 86 0.46 106 0.00
HTR3C p.Q37H 3 183772552 G C 53 0.00 73 0.39 69 0.00
POLR2B p.R1141H 4 57896552 G A 45 0.00 44 0.39 87 0.00
CCDC36 p.K176T 3 49282161 A C 39 0.00 86 0.36 132 0.00
GRID1 p.A738T 10 87379772 C T 44 0.00 44 0.33 102 0.00
WDFY4 p.L2168H 10 50038907 T A 19 0.00 28 0.25 54 0.00
GNL2 p.E644G 1 38033896 T C 44 0.00 81 0.25 81 0.00
PCSK6 p.R225* 15 101970251 G A 40 0.03 41 0.24 104 0.00
RICTOR p.I920M 5 38953593 A C 41 0.00 88 0.23 149 0.00
TARDBP p.C39Y 1 11073900 G A 51 0.00 73 0.22 86 0.00
TOPBP1 p.H735D 3 133358833 G C 118 0.00 179 0.22 258 0.00
ADAMTS9 p.C553Y 3 64633668 C T 35 0.00 56 0.21 63 0.00
ENTPD8 p.L479V 9 140329419 G C 45 0.00 144 0.19 248 0.00
NABP2 p.T40S 12 56619195 A T 75 0.03 176 0.18 191 0.00
KRT2 p.R122H 12 53045562 C T 45 0.00 89 0.18 102 0.00
OR5K3 p.F32Lfs57* 3 98109599 - T 72 0.00 84 0.18 75 0.00
CLDN18 p.T4Sfs140* 3 137717718 TGACTGCC - 63 0.00 108 0.18 57 0.00
SRD5A2 p.S41R 2 31805847 G T 14 0.00 24 0.17 49 0.00
FLRT2 p.A503V 14 86089366 C T 65 0.02 88 0.15 164 0.00
PIP4K2C p.Q36H 12 57985180 G C 56 0.00 241 0.15 249 0.00
PEX19 p.N284K 1 160249389 A C 28 0.00 35 0.14 46 0.00
KAL1 p.Q196H X 8555973 C A 37 0.03 49 0.14 56 0.00
TTC21B p.T1165M 2 166740494 G A 108 0.02 127 0.13 173 0.00
ARRB1 p.L339M 11 74979987 G T 43 0.02 30 0.13 117 0.00
CAPRIN2 p.S278* 12 30886622 G C 129 0.00 397 0.13 216 0.00
VPS33B p.R290W 15 91549274 G A 27 0.00 32 0.13 48 0.00
RAPSN p.A265D 11 47463281 G T 33 0.00 80 0.13 121 0.00
UBE4A p.L813W 11 118257157 T G 32 0.00 41 0.12 90 0.00
BARD1 p.W629* 2 215609807 C T 49 0.00 58 0.12 115 0.00
OPN3 p.D191H 1 241767684 C G 65 0.00 105 0.11 129 0.00
KRT2 p.R275C 12 53043736 G A 117 0.01 146 0.10 218 0.00
BTNL9 p.D109N 5 180475142 G A 41 0.00 61 0.10 101 0.00
COBLL1 p.S610C 2 165555957 T A 229 0.00 262 0.10 461 0.00
BCL11A p.I832M 2 60687551 T C 48 0.00 91 0.00 57 0.30
SLC40A1 p.S301P 2 190428811 A G 84 0.00 146 0.00 65 0.23
VCAN p.S1634T 5 82833722 T A 60 0.02 135 0.00 63 0.22
WNT16 p.G157S 7 120971854 G A 106 0.00 268 0.00 126 0.19
GPR98 p.S3562N 5 90040998 G A 62 0.00 91 0.00 38 0.13
SPOCD1 p.G1136C 1 32256449 C A 19 0.00 64 0.00 40 0.13
PRPF8 p.L380I 17 1583054 G T 23 0.00 69 0.00 44 0.11
FBP1 p.R255H 9 97367800 C T 36 0.00 86 0.00 46 0.11
APLF p.H307N 2 68765118 C A 54 0.00 132 0.00 68 0.10
ACBD5 p.W511C 10 27493401 C A 88 0.00 233 0.00 107 0.33
LARP6 p.K302* 15 71124963 T A 76 0.00 192 0.00 151 0.27
SCAPER p.T451S 15 77059327 T A 131 0.00 271 0.00 137 0.22
KRAS p.G12R 12 25398285 C G 101 0.00 589 0.00 110 0.20





























Figure 2.3. BaseScope in-situ RNA detection of mutant KRAS in FFPE IPMN tissues. A. Hematoxylin stain of low-
grade IPMN sample IPC09 B. B-C. Representative image of Area 1 probed for either KRAS p.G12D (B) or KRAS p.G12V 
(C). D-E. Representative image of Area 2 probed for either KRAS p.G12D (D) or KRAS p.G12V (E). F-G. Representative 
image of Area 3 probed for either KRAS p.G12D (F) or KRAS p.G12V (G). H. Hematoxylin stain of IPC09 B overlaid with 
green, indicating areas of positive staining for KRAS p.G12D or red, indicating areas of positive staining for KRAS 
p.G12V. Dark red dots designate positive signal (black arrows point to representative cells with positive staining). Nuclei 


















































Figure 2.4. Convergent evolution and heterogeneity in later-occurring driver genes in IPMNs with high-grade 
dysplasia. A-B. Mutations are presented in tables with each row representing a mutation and each column representing a 
sample. Blue color indicates a mutation call, with variant allele frequencies in each cell of the table. Both depicted IPMNs 
have multiple mutations called in a later-driver gene. A. IPC16, a high-grade IPMN, has four distinct RNF43 mutations. B. 
IPC20, a high-grade IPMN, has two different RNF43 mutations and four distinct TP53 mutations. C-D. The 20 IPMNs are 
represented around the perimeter of the circle in clockwise numerical order – grade of dysplasia/analysis-type for each 
IPMN is indicated by the colored key. Only heterogeneous mutations are displayed (not all mutations). Each colored 
rectangle represents a heterogeneous mutation in a given gene, which is indicated by colored key. The heterogeneous 
mutations in each IPMN are presented by gene in low-grade and whole lesion analysis of high-grade IPMNs (C) and low-





Table 2.7. Comparison of Mutations Identified in Multi-Region Sequencing and Cyst Fluid Molecular Analysis in IPC03 
 
 
Mutation VAF cyst fluid VAF multi-region
# of regions with 
mutation present at 
>5% VAF Mutation VAF multi-region
# of regions with 
mutation present at 
>5% VAF
Region covered by 
cyst fluid Mutation VAF cyst fluid
KRAS p.G12V 0.27 0.05-0.45 5 KRAS p.G12R 0.16-0.33 3 Y
KRAS p.G12D 0.17 1 Y
GNAS p.R201H 0.10 1 Y
CDKN2A p.R80P 0.06 1 N






Figure 2.5. Revised clonal evolution model for early pancreatic tumorigenesis. Multiple, independent clones arise with distinct mutations in early driver genes 
(i.e. GNAS and/or KRAS) (blue, purple, and light green). Early in tumorigenesis, some selective pressures eventually lead to expansion of a dominant clone 
(green). Often during later-stages of tumorigenesis, convergent evolution leads to multiple mutations in the same later-occurring driver gene (i.e. RNF43, TP53) 




















Single-cell sequencing reveals genetic 


















Single-cell sequencing can resolve individual cellular genotypes and definitively 
assign mutations to each clone, providing a more complete understanding of 
intratumoral genetic heterogeneity. Multiple recent studies have reported reliable single-
cell sequencing of human cancer specimens[101–104]. However, to our knowledge, the 
genotypes of individual cells in pancreatic precursor lesions have yet to be examined. In 
this study, we assess genetic heterogeneity in IPMNs by identifying somatic mutations 
in single neoplastic cells from fresh IPMN tissue from surgical resections, providing new 
insights into the clonal structure of these pancreatic cancer precursor lesions 
Materials and Methods 
Specimen acquisition. This study was approved by the Institutional Review Board at 
The Johns Hopkins Hospital. We prospectively collected samples from ten patients 
diagnosed with IPMN who had undergone surgical resection at the Johns Hopkins 
Hospital between 2015 and 2016. Neoplastic tissue was harvested by a subspecialized 
pancreatic pathologist; fragments of cyst call were harvested from one to four different 
regions of IPMN after confirmation of diagnosis. 
Tissue processing and isolation of single cells. The harvested neoplastic tissues 
were immediately minced using a sterile scalpel and tweezers. Minced tissues were 
then enzymatically digested using optimized MEM containing 375 units/ml collagenase 
type 4, 250 units/ml hyaluronidase, 2.4 units/ml dispase II, and 1% FBS, and incubated 
in a shaking incubator at 37C for 1 hour. Subsequently, the digested cell solution was 




with 10% FBS. Fresh normal duodenum or spleen was harvested at the same time, 
flash frozen, and stored at -80C until DNA extraction.  
Fluorescence-activated cell sorting. The single cell suspension was adjusted to the 
concentration of 1 million cells/200ul HBSS containing 5% FBS. The cells were labeled 
with 1.5ug/ml Anti-EpCAM antibody [VU-1D9] (Phycoerythrin) (abcam, ab112068) and 
incubated on ice for 30 min. Following centrifugation, cells were washed twice with 
HBSS. Cells were resuspended and adjusted to the concentration of 1 million cells/1ml 
containing 2% FBS, and then labeled with 5uM Vybrant® DyeCycle™ Violet Stain (Life 
Technologies, V35003) and incubated using a water bath at 37°C for 30 min. Before 
sorting, 1ug/ml propridium iodide (PI) (Sigma Aldrich, P4864) was added to the cell 
solution, which was then filtered through 35um mesh. Single viable epithelial cells in 
G2/M phase were sorted using MoFlo Legacy cell sorter (Beckman Coulter, Inc., Miami, 
FL) into individual wells of a 96-well plate. First, we selected intact cells based on 
forward scatter (FS) and side scatter (SS), and we then selected the population to 
exclude PI-positive cells to ensure the presence of only viable cells. We subsequently 
selected EpCAM-positive cells. In addition, as first reported by Wang and 
colleagues[103], we specifically selected cells that had replicated their DNA to improve 
the efficiency of the subsequent whole genome amplification – this was accomplished 
with DyeCycle Violet staining and selection of cells in G2/M phase, according to 
Vybrant® DyeCycle™ Violet Stain intensity (using the EpCAM-negative population as a 
control for G1 DNA content). We isolated 23-46 single cells per harvested tissue 




isolated for each tissue sample, and when an adequate number of cells were available, 
a second bulk sample of 30,000 cells was also isolated for each tissue sample. 
Preparation of genomic DNA. Multiple displacement amplification (MDA) using 
isothermal random priming and extension with φ29 polymerase was conducted on the 
sorted single cells using the REPLI-g Single Cell kit (Qiagen, 150345) according to the 
manufacturer’s instructions - this WGA approach leads to higher coverage and lower 
error rate compared to other amplification approaches[105,106]. The same kit was used 
to amplify DNA from the 1,000-cell bulk sample. Amplified DNA was purified by the 
ethanol precipitation method according to the manufacturer’s protocol. Genomic DNA 
from the sorted bulk cells was isolated using the QIAamp® DNA Micro Kit (Qiagen, 
56304), and genomic DNA from frozen normal tissue was isolated using the QIAamp® 
DNA Mini Kit (Qiagen, 51304) according to the manufacturer’s instructions. All prepared 
samples were quantified by quantitative PCR (qPCR) targeting long interspersed 
nuclear elements (LINE) using StepOnePlus™ Real-Time PCR System (ThermoFisher 
scientific) {Rago, 2007 #395}.  PCR was performed using Power SYBR Green Master 
Mix (ThermoFisher scientific, 4367659) according to the manufacturer’s instructions. 
The LINE primes were designed as follows: 5’-AAAGCCGCTCAACTACATGG-3’ 
(forward) and 5’-TGCTTTGAATGCGTCCCAGAG-3’ (reverse). The real-time PCR 
conditions were as follows: 50°C for 2 minutes, 94°C for 2 minutes, 40 cycles of 94°C 
for 10 seconds, 58°C for 15 seconds, and 70°C for 30 seconds, 95°C for 15 seconds, 
60°C for 30 seconds, and 95°C for 15 seconds. 
Evaluation of amplification efficiency. To determine quality of the WGA products for 




Kit (Qiagen, 206152). Ten pairs of primers were designed to target ten genes located on 
different chromosomes. The PCR conditions were as follows: 95°C for 5 minutes, 35 
cycles of 95°C for 30 seconds, 63°C for 3 minutes, and 72°C for 40 seconds, and 68°C 
for 10 minutes. PCR products were run on 2% agarose gels. WGA products were 
selected as successfully amplified products by detection of the DNA bands in at least 
8/10 (80%) PCR products[104,107,108].     
Targeted deep sequencing in 11 genes. Using the Ion AmpliSeq Designer, we 
designed an Ion AmpliSeq custom panel 142 primer pairs in 11 genes reported 
previously: ARID1A, TGFBR2, PIK3CA, BRAF, CDKN2A, KRAS, TP53, MAP2K4, 
RNF43, SMAD4, and GNAS. Additional primers were designed to target single 
nucleotide polymorphisms (SNPs) with high minor allele frequency archived by National 
Center for Biotechnology Information (NCBI) in or near these genes, for a total of 166 
primer pairs in the panel. Sample DNA (20ng/primer pool) was amplified and the 
libraries were prepared using Ion AmpliSeq 2.0 Library Kit (Life Technologies) according 
to the manufacturer’s protocol. Individual samples were barcoded, pooled, and 
templated with the OneTouch2 system (Life technologies), and subsequently 
sequenced on the Ion Torrent Personal Genome Machine (Life Technologies). Targeted 
sequencing was performed on all single cells that amplified 8/10 products in our 
multiplex PCR assay (see above), one bulk tumor sample per tissue section, and one 
bulk normal sample per patient. For IP10 section B, IP10 section C, and IP16 section C, 
we used an unamplified tumor bulk sample (from 30,000 sorted cells). For the remaining 




WGA as described above) because we were unable to sort an adequate cell number for 
an unamplified bulk sample. 
Mutation calling and imputation of undetermined genotypes. For each IPMN single-
cell, bulk tumor, or bulk normal sample, reads were mapped to the human reference 
genome version hg19 with BWA-mem[81], and the resulting BAM files were processed 
using the Genome Analysis ToolKit (GATK). For each of the single cell BAMs, variant 
calling was done with GATK HaplotypeCaller (independently for each one)[80].  Each 
variant site was classified as either harboring a somatic mutation (VAF≥5% and 
alternate read count ≥ 5, and normal bulk VAF<2% and alternate read count <4, 
provided that normal bulk coverage ≥100X), consistent with reference (coverage≥100 
and VAF<0.2% and alternate read count <2), or indeterminate. Mutation profile matrices 
(mutation by single-cell) were constructed – values of 0, 1, or 0.5 were assigned to each 
matrix element, depending on whether the mutation was present, absent, or if its status 
was indeterminate, in the corresponding single cell. Only mutations called in at least two 
single cells or one single cell and one bulk IPMN sample were considered in further 
analysis. To impute indeterminate elements, we applied an iterative single-cell genotype 
clustering algorithm using minimum distance linkage to impute the status of 
indeterminate mutations[109].  
Allelic dropout estimation. The normal bulk samples were used to estimate single-cell 
allelic dropout (ADO) rates. As described above, we applied GATK's HaplotypeCaller to 
call sites in the normal bulk harboring a germline variant and mpileup to compute VAFs 
and alternate read counts[110]. Each site called by HaplotypeCaller as heterozygous in 




or VAF>95%). A single cell's ADO rate was computed as the fraction of heterozygous 
sites in the bulk normal that had sufficiently high coverage (≥100x) but were found to be 
homozygous in that single cell. We removed single cells with fewer than 51% 
heterozygous SNPs correctly called as heterozygous. The 51% threshold was 
determined by standard box-plot techniques. Finally, single cells for which fewer than 5 
of the heterozygous sites in the bulk normal had sufficiently high coverage were also 
excluded from further analysis, as their ADO rate could not be accurately determined. 
The average allelic dropout (ADO) rate across all single cells was 13% after outlier 
removal. 
Analysis of technical controls. Three different technical controls were processed as 
described above in order to calculate the false positive rate (FPR) of our single-cell 
analysis pipeline. First, 28 single cells from the Pa01 cell line were sorted as described 
above, followed by whole genome amplification and multiplex PCR to assay 
amplification efficiency. In addition, four bulk samples of this cell line were analyzed, 
including one sample of 5 x 106 cells without amplification and three samples of 10 cells 
that underwent whole genome amplification. Single-cell and bulk samples were 
sequenced using the Ion AmpliSeq Cancer Hotspot Panel v2, and mutations were 
called as described above. In the absence of a matched normal sample, we could not 
distinguish somatic mutations. Instead, the mutations called in the bulk samples (which 
included both germline and somatic mutations) were considered true positives, while 
any mutation called in a single cell but absent in the bulk was considered a false 
positive – this resulted in a FPR of 2.5 x 10-5 false positives per base pair sequenced. 




however, it does not account for potential errors induced by tissue processing steps. As 
such, we included two additional technical controls derived from resected human 
pancreatic samples. First, we used normal cells isolated from PDAC samples. 
Specifically, tissue was harvested from pancreata from 6 PDAC patients, followed by 
tissue digestion, single cell isolation, whole genome amplification, multiplex PCR, and 
targeted sequencing using our AmpliSeq custom panel as described above. Mutations 
were called as described above. Due to the low neoplastic cellularity of PDACs, a 
sizeable proportion of the analyzed cells were non-neoplastic. Thus, we defined 
“normal” cells as those that had no somatic mutations that were present in the bulk 
sample from the same patient. Any mutation called in a “normal” cell was considered a 
false positive – in total, we analyzed 23 single normal cells from 3 PDAC samples and 
calculated a FPR of 3.0 x 10-5 false positives per base pair sequenced. As a third 
technical control, we used single cells sequenced from an intraductal oncocytic papillary 
neoplasm (IOPN), which were processed and sequenced with an identical protocol to 
the our experimental IPMNs. Because IOPNs lack mutations in the pancreatic driver 
genes in our custom panel and all bulk samples from this lesion lacked somatic 
mutations, we considered any somatic mutation in this lesion to be a false positive – we 
calculated a FPR of 3.1 x 10-5 false positives per base pair sequenced. Importantly, the 
FPR is consistent across these three independent technical controls, suggesting that it 
is protocol-specific and does not vary substantially between different experimental 
samples. Moreover, the same false positive mutation was not called in multiple single 
cells in any of the technical controls, highlighting that the mutations identified in our 





Clinicopathological data. Clinicopathological data of the ten cases are summarized in 
Table 3.1. All patients had a histologically confirmed diagnosis of IPMN. Of the ten 
IPMNs analyzed, seven cases were non-invasive (three with low-grade dysplasia and 
four with high-grade dysplasia), while three had adjacent invasive carcinomas (two 
invasive ductal adenocarcinomas and one invasive colloid carcinoma). The IPMNs were 
classified as gastric (7 cases), intestinal (2 cases), and oncocytic (1 case) histological 
subtypes. The number of somatic mutations called in the ten analyzed IPMNs ranged 
from 0 to 10 (Figures 3.1-3.4). Five IPMNs had different mutations in the same driver 
gene called in different single cells. 
Early driver gene mutations. Of the ten IPMNs analyzed, nine harbored KRAS and/or 
GNAS mutations (Table 3.1). We identified two IPMNs with genetic heterogeneity with 
respect to these early driver gene mutations. One case (IP27) was diagnosed as an 
IPMN with high-grade dysplasia - two pieces of the cyst lining were harvested from the 
same grossly-evident cyst. Two different distinct KRAS mutations were identified in this 
neoplasm (Figure 3.1A). The majority of cells that harbored a GNAS p.R201H mutation 
also had a KRAS p.G12D mutation. Three cells lacked both the GNAS p.R201H and 
KRAS p.G12D mutations but had a different mutation in KRAS (p.G12R). These data 
suggest this neoplasm could have originated from two independent clones, each with 
unique mutations in early driver genes and without any shared genetic alterations. In the 
second IPMN (IP16), there were two adjacent grossly-evident cysts (samples A and B) 
as well as a distinct firm area (sample C). Histologic examination revealed IPMN with 




(suggesting that they likely represented the same IPMN) and infiltrating ductal 
adenocarcinoma in the firm area. Two different clones with unique KRAS mutations 
were identified in the cysts – a clone with KRAS p.G12D was identified in both IPMN 
samples, while a clone with KRAS p.G12V was limited to a single IPMN sample. A 
mutation in TP53 (p.R175H) occurred in a subset of cells with KRAS p.G12D. In 
contrast, the invasive cancer harbored a different KRAS mutation (p.G12R) as well as a 
unique TP53 mutation (p.C229*) (Figure 3.1B). These results suggest two independent 
clones within the IPMNs, as well as a genetically distinct invasive adenocarcinoma, all 
in a relatively small area of this patient’s pancreas. 
In the other seven cases, shared KRAS and/or GNAS mutations were present in 
the vast majority of neoplastic cells analyzed, suggesting that these were clonal 
mutations.  
Mutations in other driver genes. We identified mutations in RNF43 in three IPMNs 
(Table 3.1). The first RNF43-mutant case (IP22) was diagnosed as IPMN with low-
grade dysplasia and harbored six different RNF43 mutations, including three frameshift 
insertion/deletion mutations, two missense mutations, and one binucleotide substitution. 
The binucleotide substitution (p.VD299VY) occurred in the same clone as one missense 
mutation (p.G166V), suggesting biallelic RNF43 alteration in this clone. The remaining 
RNF43 mutations were mutually exclusive, suggesting the presence of five separate 
clones with unique alterations in RNF43 (Figure 3.2A). In another IPMN with high-grade 
dysplasia (IP24), we identified three RNF43 mutations each present in different single 
cell populations: p.A11Lfs occurred in three single cells from section A, while p.G207D 




tissue section (Figure 3.2B). In the third RNF43-mutant neoplasm (IP10), which was 
diagnosed as colloid carcinoma, the RNF43 mutation (p.L12Dfs) occurred with 
mutations in GNAS (p.R201C) and CDKN2A (p.G55Afs) in all cells analyzed from this 
IPMN (Figure 3.4). However, we analyzed very few single cells in this case and thus 
cannot confidently determine the clonality of these mutations. 
We also identified an IPMN with low-grade dysplasia (IP12) that harbored three 
different inactivating ARID1A mutations in addition to a clonal KRAS mutation (Figure 
3.4A). One mutation (p.A826Efs) occurred in 83% of single cells. The other two ARID1A 
mutations (p.P570Lfs and p.E1786Gfs) were mutually exclusive, occurring in in 25% 
and 13% of single cells, respectively, and were only present in cells with the first 
ARID1A alteration. Three other IPMNs IP16, IP27 (Figure 3.1), and IP08 (Figure 3.3B), 
also had subclonal ARID1A mutations, each present in only two to three single cells. 
Mutations in other frequently altered driver genes in pancreatic ductal neoplasia 
occurred uncommonly in our cohort. Two IPMNs (IP08 and IP10) had clonal mutations 
in CDKN2A, while IP22 had a subclonal mutation in this gene. Although our cohort 
included four cases of IPMN with high-grade dysplasia and three cases of IPMN with 
associated adenocarcinoma, we identified TP53 mutations in only one patient – unique 
TP53 mutations were identified in IPMN and adjacent carcinoma in IP16. In addition, we 
only identified single mutations in SMAD4 and in TGFBR2. Intriguingly, the SMAD4 
mutation co-occurred with an RNF43 mutation in a subclone of IP22, which had only 





Of note, in the single case of intraductal oncocytic papillary neoplasm (IOPN) 
(IP20), we did not identify any mutations in the genes in our panel, consistent with 
recent reports that these neoplasms are genetically distinct from other subtypes of 
IPMN[8]. 
Discussion 
In this study, we provide the first single-cell genetic analysis of precursor lesions 
to invasive pancreatic cancer. In addition to demonstrating the feasibility of this type of 
analysis, these results provide insights into the genetic heterogeneity of early pancreatic 
tumorigenesis. 
The majority of the IPMNs (seven of ten) had KRAS and/or GNAS mutations that 
were shared by the vast majority of analyzed cells. As the proportion of wild-type cells 
was similar to our ADO rate, the data suggest that these mutations are clonal in these 
IPMNs, that is, present in every neoplastic cell. In two of the ten IPMNs, we identified 
multiple clones with distinct KRAS mutations, suggesting the presence of independent 
neoplasms or neoplasms in which the shared genetic alteration does not occur in any of 
the known driver genes. In one IPMN (case IP16), the clone in the invasive carcinoma 
was genetically distinct from the two clones in the IPMN, consistent with an IPMN with 
concomitant rather than associated invasive adenocarcinoma[111]. The IPMNs in both 
IP16 and IP27 had multiple KRAS mutations within the same grossly defined IPMN. In 
these cases, the two clones were not grossly separated but instead were identified in 
the same small tissue fragment harvested from the wall of the IPMN. These data could 
suggest that these IPMNs were polyclonal, made up of multiple clones without a shared 




were monoclonal but initiated by an unidentified alteration prior to the development of 
KRAS mutations. The existence of such an earlier initiating alteration in pancreatic 
tumorigenesis has not yet been described. 
 The results of these studies also provide insight into the timing of driver gene 
mutations in pancreatic tumorigenesis. Like previous studies, our data suggest that 
mutations in KRAS and GNAS occur very early, as they are clonal in the majority of 
neoplasms in our study. In the IPMNs in which mutations in these genes were 
subclonal, there were no clonal mutations in other driver genes, suggesting that KRAS 
and GNAS are the earliest known driver genes in the pancreas. In contrast, mutations in 
RNF43 and ARID1A are clearly subclonal in a subset of IPMNs, indicating that these 
mutations occur after the clonal KRAS or GNAS mutations. The persistence of cells 
without mutations in these genes highlights the heterogeneous clonal composition of 
IPMNs, perhaps suggesting that these driver gene mutations only provide slight 
selective advantage to certain cells within the tumor microenvironment. Of note, rare 
single cells (such as C_10 in IP10 and B_29 in IP24) lack mutations in KRAS and 
GNAS but have mutations in other driver genes. We interpret the lack of KRAS/GNAS 
mutations as a false negative result due to allelic drop out, a known artifact in single-cell 
sequencing data due to limited starting material. However, we cannot exclude that the 
identified genotypes are accurate, raising the possibility of a different sequence of driver 
gene mutations in a subset of cases. 
 In addition to mixtures of wild-type and mutant cells, our data also demonstrate 
that a subset of IPMNs consist of mixtures of neoplastic cells with different mutations in 




five different clones, each with unique mutations in RNF43. Similarly, IP24 has three 
unique mutually exclusive RNF43 mutations. In contrast, IP12 has three different 
ARID1A mutations, two of which occurred as mutually exclusive second hits in small 
subclones of cells with the first ARID1A mutation. These IPMNs provide snapshots of 
the acquisition of tumor suppressor gene mutations in precursor lesions, suggesting a 
more complicated process than the sequential acquisition of two “hits”. Moreover, they 
suggest the presence of convergent evolution in at least a subset of IPMNs, in which 
mutations in a specific driver are strongly selected at a certain time point in 
tumorigenesis, resulting in multiple clones independently acquiring unique mutations in 
the selected gene. The identification of somatic mutations in ARID1A in IPMNs is also 
novel – although somatic mutations in this well-characterized tumor suppressor gene 
have been previously reported in PDAC, this is the first report of frequent ARID1A 
alterations in IPMNs[112]. 
 A few technical considerations in our study are important to note. First, like Wang 
et al, we specifically isolated cells with replicated DNA (G2/M cells) in order to provide 
more template and thus improve the efficiency of our single-cell whole genome 
amplification[103]. Although this approach improves the technical success of our assay, 
selection of this subset does bias our analysis to proliferating cells. Even with this 
caveat, our data show that these cells represent a broad spectrum of clones with 
varying driver gene mutations. Comparison of mutation calls from the bulk and single-
cell analyses also provides important insights into the utility of detailed single-cell 
analysis. Some of the subclonal mutations in RNF43 in IP22 and IP24 were absent from 




average coverage of almost 700X in bulk samples. Although our data suggest that 
single-cell sequencing has an increased sensitivity to detect rare clones, it is possible 
that ultra-deep sequencing (>1000X) of bulk tissue could achieve a similar sensitivity. 
Still, an ultra-deep bulk approach cannot assign rare mutations with similar frequency to 
specific clones, which is the true strength of single-cell analyses. There was also a 
mutation that was identified in a bulk sample but not in any single cells from that section 
(p.V31Dfs in RNF43 in section A of IP22). This mutation had very low variant allele 
frequency in the bulk sample, suggesting that the number of single cells analyzed was 
likely not adequate to identify the rare cells with this mutation; such sensitivity issues will 
decrease as technical improvements allow analysis of larger numbers of single cells per 
sample. Overall, these findings highlight the strength of paired single-cell and bulk 
analysis of tissue samples, as the approaches are complementary. Finally, our data 
highlight the importance of assays to evaluate the quality of single-cell DNA 
amplification. Through our two-step filtering procedure (multiplex PCR, analysis of 
heterozygous germline SNPs), we restricted our analyses to only the most robustly 
amplified cells. Although this filtering excluded a significant proportion of the initially 
sorted cells (57%), it provides confidence in the quality of the data that passed these 
rigorous filters. In particular, we report a low ADO of 13% in analyzed cells, likely due to 
our analysis of only the most robustly amplified cells. Moreover, our FPR is consistent 
with those reported in other single-cell studies, and none of our control samples had 
false positive mutations that occurred in more than one single cell. This strongly 
suggests that even the rare subclones identified in our samples are unlikely to be 




Single-cell mutation calling remains an active research area in computational 
genomics, and the pipeline developed for this data set is novel. We found that currently 
available protocols to call mutations were not sufficiently optimized to take advantage of 
our sequencing data, which included IPMN single-cell samples, IPMN bulk samples, 
and matched normal bulk samples for each case in our study. The analysis pipeline 
developed in this work combines a standard variant caller designed for high specificity 
in bulk tissues and enhancements to handle single-cell amplification bias and increase 
caller sensitivity through multi-sample information pooling. The final set of mutation calls 
were a product of multiple tools and empirically selected thresholds; slight variations of 
these thresholds yielded stable results. We also utilized imputation to infer genotypes of 
cells for which sequencing data was indeterminate. Of note, imputation was not used in 
our study to identify new mutations but only to resolve indeterminate calls of mutations 
that had already been convincingly identified in other cells. Thus, this algorithm could 
only change the proportion of cells within an IPMN with a particular mutation. 
 Overall, our data provide the first insights into genetic heterogeneity of pancreatic 
cancer precursors at the single-cell level. Because our study encompassed a limited 
sample size of ten IPMNs, it is not possible to definitively determine the prevalence of 
this heterogeneity in patients with IPMN. Analysis of more cells and more lesions will be 
required to systematically catalogue this genetic heterogeneity and to correlate it with 
clinical features, such as grade of dysplasia and risk of malignant progression. 
Moreover, most of the IPMNs analyzed in our study were gastric-type, so our study 
provides limited insights into heterogeneity in other IPMN subtypes – all-inclusive 




studies to comprehensively describe the nature and extent of this single-cell genetic 
heterogeneity in IPMNs. Still, our studies suggest complex patterns of clonal evolution 
in preinvasive lesions. In addition, more extensive sequencing (such as whole exome 
sequencing) and identification of different types of alterations (such as copy number 
changes) will provide a more complete picture of clonal evolution in IPMNs, but our 
driver-focused approach provides key insights into heterogeneity of alterations that drive 
pancreatic tumorigenesis. Genetic heterogeneity with respect to these driver genes is 
most likely to have functional consequences in the heterogeneous clones and thus is 















Table 3.1. Clinicopathological and molecular data from analyzed IPMNs 
 
 






Sections Mutations identified 
IP04 M 76 Head Intestinal IPMN with HGD IPMN 
A: IPMN          
F: IPMN         
G: IPMN 
GNAS(p.R201C) 





A: carcinoma  








B: IPMN         
C: IPMN 
GNAS(p.R201C),  RNF43(p.L12Dfs),  
CDKN2A(p.G55Afs) 
IP11 M 78 Head Gastric IPMN with LGD+  IPMN A: IPMN KRAS(p.G12D),  GNAS(p.R201C) 
IP12 M 59 Tail Gastric IPMN with LGD  IPMN 
B: IPMN         
C: IPMN 
KRAS(p.G12D),  ARID1A(p.P70Lfs, p.A826Efs, 
p.E1786Gfs) 





A: IPMN         
B: IPMN          
C: carcinoma 
KRAS(p.G12D, p.G12V, p.G12R),  TP53(p.175H,  
p.C229*), ARID1A(p.T1031I), TGFBR2(p.R232Q),  
IP20 F 85 Tail Oncocytic IPMN with HGD IPMN 
A: IPMN             
B: IPMN           
C: IPMN           
D: IPMN 
None 
IP22 M 65 Tail Gastric IPMN with LGD IPMN 
A: IPMN        
B: IPMN 
KRAS(p.G12V), GNAS(p.R201C), 
RNF43(p.G3Sfs, p.V31Dfs, p.C91Y, p.G166V, 
p.VD299VY,  p.H420Pfs), SMAD4 (p.E205K), 
CDKN2A(p.H83D)  
IP24 F 63 Head Gastric IPMN with HGD+  IPMN 
A: IPMN        
B: IPMN 
KRAS(p.G12V),  GNAS(p.R201C),  
RNF43(p.A11Lfs, p.T28I, p.G207D) 
IP27 M 67 Head Gastric IPMN with HGD IPMN 
A: IPMN        
B: IPMN 
KRAS(p.G12D, p.G12R), GNAS(p.R201H), 
ARID1A(p.M841Ifs) 
*The carcinoma was not identified at the time of specimen processing and was not sampled for this study.   



















Figure 3.1. Somatic mutations identified in single cells from IPMNs with multiple KRAS 
mutations. Somatic mutations are presented in heatmaps with each row representing a 
mutation and each column representing a single cell. Single cells are designated by their tissue 
section (A-C) and cell number. Cells and mutations were clustered with Euclidean distance bi-
clustering. The colors indicate the mutation calls after imputation, with red indicating mutant and 
blue indicating wild-type. Variant allele frequencies of the identified mutations in bulk samples 
from each section are indicated on the right. Both depicted IPMNs have multiple unique KRAS 
mutations. The majority of cells in IP27 (A), a gastric-type IPMN with high-grade dysplasia, have 
p.G12D in KRAS (as well as p.R201H in GNAS), while a small subclone lacks these mutations 
and instead has p.G12R in KRAS. IP16 (B) represents a gastric-type IPMN (sections A and B) 
with an adjacent ductal adenocarcinoma (section C). In this case, the IPMN contained two 
unique and mutually exclusive KRAS mutations, while the cancer had a third KRAS mutation as 








Figure 3.2. Somatic mutations identified in single cells from IPMNs with multiple RNF43 
mutations. Somatic mutations are presented in heatmaps with each row representing a 
mutation and each column representing a single cell. Single cells are designated by their tissue 
section (A-C) and cell number. Cells and mutations were clustered with Euclidean distance bi-
clustering. The colors indicate the mutation calls after imputation, with red indicating mutant and 
blue indicating wild-type. Variant allele frequencies of the identified mutations in bulk samples 
from each section are indicated on the right. Both depicted IPMNs have multiple unique RNF43 
mutations, with three mutually exclusive RNF43 mutations in IP24 (A) and five mutually 






Figure 3.3. Somatic mutations identified in single cells from IPMNs with subclonal 
ARID1A mutations. Somatic mutations are presented in heatmaps with each row representing 
a mutation and each column representing a single cell. Single cells are designated by their 
tissue section (A-C) and cell number. Cells and mutations were clustered with Euclidean 
distance bi-clustering. The colors indicate the mutation calls after imputation, with red indicating 
mutant and blue indicating wild-type. Variant allele frequencies of the identified mutations in bulk 
samples from each section are indicated on the right. Both depicted IPMNs have subclonal 
ARID1A mutations. In IP12 (A), a gastric IPMN with low-grade dysplasia, there was a subclonal 
inactivating mutation representing a first hit in this tumor suppressor gene as well as two 
mutually exclusive second hits, each present in non-overlapping subclones. In IP08 (B), an 
IPMN with high-grade dysplasia, there is a single subclonal ARID1A mutation present in only 











Figure 3.4. Somatic mutations identified in single cells from remaining cases. Somatic 
mutations are presented in heatmaps with each row representing a mutation and each column 
representing a single cell. Single cells are designated by their tissue section and/or cell number. 
Cells and mutations were clustered with Euclidean distance bi-clustering. The colors indicate 
the mutation calls after imputation, with red indicating mutant and blue indicating wild-type. 
Variant allele frequencies of the identified mutations in bulk samples from each section are 
indicated on the right. All depicted IPMNs have the driver mutation(s) present in every cell. In 
IP04, an IPMN with high-grade dysplasia, there is a GNAS p.R201C mutation. In IP10, an IPMN 
with high-grade dysplasia, there are clonal GNAS p.R201C, RNF43 p.L12Dfs, and CDKN2A 
p.G55Afs mutations. In IP11, a gastric-type IPMN with low-grade dysplasia, there are clonal 






































 This work represents some of the first data describing the polyclonal origin of 
pancreatic precancers. The results of these studies have broadened our knowledge 
regarding somatic driver gene heterogeneity in pancreatic neoplasia, which have 
substantial implications for current early detection approaches and for our current 
understanding of the origins of pancreatic tumorigenesis. 
Implications for field cancerization in the pancreas 
 A cancerized field is generally defined as a group of cells that are considered to 
be further along an evolutionary path towards cancer, but do not possess all the traits 
required for malignancy, and thus incapable of growing into a tumor[113,114]. The 
concept of field cancerization was first proposed by Slaughter et al. after observing 
microscopically abnormal epithelial fields adjacent to and, in some cases, immediately 
surrounding areas of oral squamous carcinoma[115]. Several decades later, improved 
molecular biological techniques and the advent of genetic sequencing have provided 
strong evidence for field cancerization in many tumor types. For example, a recent 
study found somatic driver gene alterations in normal airway epithelia, which were also 
shared with their matched non-small cell lung cancer (NSCLC), suggesting these 
variants were present prior to tumor formation and underwent clonal expansion during 
tumorigenesis[116]. In another study, Tao et al. demonstrated that spontaneous 
promoter hypermethylation, leading to epigenetic silencing, creates a permissive 
environment for oncogenic alterations (i.e. BRAF p.V600E) in a mouse-derived colon 




To date, there has been much speculation regarding field cancerization in 
pancreas. Patients diagnosed with IPMN often present with multiple lesions – as such, 
many have proposed this multifocality supports the concept of field cancerization. 
Furthermore, several studies have utilized genetic sequencing to determine the 
“relatedness” of these multifocal tumors. Matthaei et al. performed pyrosequencing of 
KRAS, coupled with LOH analysis of chromosomes 6q and 17p, to determine that the 
majority (~70%) of multifocal IPMNs are ‘likely independent’[118]. In addition, Pea et al. 
used targeted NGS on IPMN and PDAC lesions from 13 patients who developed 
disease progression in their remnant pancreas following resection of IPMN[119]. 
Analysis of both the primary and recurrent IPMN revealed that more than half of the 
cases had genetic alterations not shared between these neoplasms and were classified 
as ‘likely independent.’ Finally, Felsenstein et al. described the genetic relationship 
between invasive carcinoma and co-occurring IPMN[22]. Interestingly, 18% of PDACs 
and co-occurring IPMNs did not share any driver gene mutation and were considered 
‘likely independent,’ despite their close anatomic proximity. Altogether, these studies 
support the concept of field cancerization in a subset of patients, which leads to an 
increased risk of neoplasia throughout the pancreas.  
The work described in Chapters 2 and 3 of this thesis provides further support for 
field cancerization, demonstrating that even a single IPMN lesion may arise from 
multiple, genetically independent clones. While the mechanism(s) driving field 
cancerization in the pancreas remains unknown, our WES data from Chapter 2 
suggests that there is not a DNA alteration preceding KRAS that initiates tumorigenesis; 




(i.e. epigenetic alteration, whole exon loss, lariat base alteration, structural alteration, 
enhancer/promoter alteration), immediately followed by KRAS mutations. Polyclonal 
origin of precancerous lesions in other organ systems has previously been 
demonstrated, including esophagus and skin[77,78,120]. Intriguingly, many of these 
organs sites have known strong carcinogen exposures which may serve as a potential 
mechanism underlying polyclonal tumor origin. It is possible that an as-yet unidentified 
environmental exposure in the pancreas serves as the field carcinogen (i.e. focal 
pancreatitis, duodenal reflux, bile acids) leading to increased DNA mutations and 
emergence of clones with KRAS and GNAS mutations. Alternatively, some of the most 
recent data regarding field cancerization in pancreas provides a link between cellular 
metabolism and propensity for KRAS mutations[121]. This study found that 
hyperglycemic conditions in pancreatic cells leads to elevated cellular O-GlcNAcylation, 
which triggers genomic instability that preferentially increases KRAS mutations. Another 
recent study found that abundance of cellular acetyl-CoA plays a key role in tumor 
formation by regulating histone acetylation and mediating acinar-to-ductal 
metaplasia[122]. Importantly, however, the investigators found that this pathway is 
mutant KRAS-mediated, and does not function in KRAS WT cells. This finding suggest 
there is another event that demarcates the emergence of precancerous lesions from the 
normal-appearing cancerized field. It is possible that certain cellular metabolic 
processes cooperate by first, inducing the acquisition of KRAS mutations in normal 
pancreatic cells, which then contribute to additional metabolic reprogramming that 
promotes tumorigenesis. Both of the aforementioned studies predominately utilized 2D 




studies should determine if KRAS mutations are present in normal human pancreatic 
tissues (i.e. ductal or acinar cells) in various disease-settings, including IPMN. 
Implications for subclonal interactions in polyclonal tumors 
The work described in Chapters 2 and 3 demonstrates that pancreatic 
precancers are polyclonal in origin, and we assume that some selective pressures lead 
to clonal dominance and expansion during tumor progression. Alternatively, pancreatic 
tumor growth may actually be supported by cross-talk between neoplastic cell 
subpopulations. Current evidence suggests that clonal evolution is not a stochastic 
process, but rather influenced by sublconal communication, such as paracrine signaling 
and cell-to-cell interactions[123]. For example, one study found that co-culturing distinct 
neoplastic subpopulations of small cell lung cancer (SCLC) led to enhanced tumor 
growth and, intriguingly, metastatic potential[124]. Others have demonstrated subclonal 
cooperation in breast cancer by utilizing GEMMs to show tumor growth is driven by 
subclones of cells which secrete tumor-promoting factors, such as IL11 and Wnt1, to 
stimulate expansion of other clones[125,126]. It is possible that similar mechanisms of 
clonal interactions are driving the progression of pancreatic precancers – as such, 
future studies should investigate the role of multiple GNAS and/or KRAS mutant clones 
in pancreatic tumor growth and malignant progression.  
Conclusions 
This thesis has provided strong evidence for the polyclonal origin of IPMNs, and 
transforms our understanding of the earliest stages of pancreatic tumorigenesis. In 
addition, these data reveal the substantial degree of driver gene heterogeneity within 




strategies. Finally, this work provides strong evidence supporting the concept of field 
cancerization in the pancreas. Discovering the mechanism(s) of this field cancerization 
will be critical for identifying individuals at highest risk for developing pancreatic 
neoplasia. This discovery has the potential to revolutionize the way clinicians screen 
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